Keystone 65 Rx HMO
Personal Choice 65℠ Rx PPO
Select Option® Rx PDP
2018 Utilization Management Criteria: Prior Authorization

PLEASE READ: THIS DOCUMENT CONTAINS INFORMATION ABOUT SOME OF THE DRUGS WE COVER IN THIS PLAN

This document was updated on 11/1/18. For more recent information or other questions, please contact our Member Help Team: Keystone 65 at 1-844-352-1699, Personal Choice 65 at 1-888-879-4293, Select Option at 1-888-678-7009 or, for TTY/TDD users, 711, seven days a week from 8 a.m. to 8 p.m. Please note that on weekends and holidays from February 15 through September 30, your call may be sent to voicemail. Or, visit www.ibxmedicare.com to use our *Formulary (List of Covered Drugs)* search tool or view a downloadable document.

When this document refers to "we," "us," or "our," it means Independence Blue Cross. When it refers to "plan" or "our plan," it means Keystone 65 Rx, Personal Choice 65 Rx, and Select Option Rx.

You must generally use network pharmacies to use your prescription drug benefit. Benefits, formulary, pharmacy network, and/or copayments/coinsurance may change on January 1, 2019, and from time to time during the year.

Independence Blue Cross offers Medicare Advantage plans with a Medicare contract. Enrollment in Independence Medicare Advantage plans depends on contract renewal.

Keystone 65: Benefits underwritten by Keystone Health Plan East, a subsidiary of Independence Blue Cross — independent licensees of the Blue Cross and Blue Shield Association.

Personal Choice 65 & Select Option: Benefits underwritten by QCC Insurance Company, a subsidiary of Independence Blue Cross — independent licensees of the Blue Cross and Blue Shield Association.

There may be restrictions to your drug coverage

Some covered drugs may have additional requirements or limits on coverage. We call this "utilization management." These requirements and limits may include:

- **Prior Authorization (PA):** Our plan requires you or your physician to get prior authorization for certain drugs. This means that you will need to get approval from our plan before you fill your prescriptions. If you don't get approval, our plan may not cover the drug. Drugs that require Prior Authorization are listed in this document.
- **Step Therapy (ST):** In some cases, our plan requires you to first try certain drugs to treat your medical condition before we will cover another drug for that condition. Drugs that require Step Therapy are listed in *2018 Utilization Management Criteria: Step Therapy*.
- **Quantity Limits (QL):** For certain drugs, our plan limits the amount of the drug that our plan will cover. Drugs that have Quantity Limits are listed in the *Keystone 65 Rx, Personal Choice 65 Rx, and Select Option Rx Formulary (List of Covered Drugs)*.

You can find out if your drug has any additional requirements or limits by looking in your plan *Formulary (List of Covered Drugs)*. You can also get more information about the restrictions applied to specific covered drugs by visiting www.ibxmedicare.com.

You can ask our plan to make an exception to these restrictions or limits, or for a list of other similar drugs that may treat your health condition. Your *Formulary (List of Covered Drugs)* and *Evidence of Coverage* will have more information about the exception request process.

How to use this document

This document, along with *2018 Utilization Management Criteria: Step Therapy*, is intended to be used with your *Formulary (List of Covered Drugs)*. If your prescription drug has the note "PA" in the "Requirements" column of the *Keystone 65 Rx, Personal Choice 65 Rx, and Select Option Rx Formulary (List of Covered Drugs)*, you can find more information on the restriction(s) in this document.

Locate your drug in the index on page 181. The restriction information includes:

- **Prior Authorization**
  - Covered uses
  - Exclusion criteria
  - Required medical information
  - Age restrictions
  - Prescriber restrictions
  - Coverage duration
  - Other criteria

Be sure to read all the information listed for your affected drug. If you have any questions, or need assistance with the information contained in this document, please call our Member Help Team: Keystone 65 at 1-844-352-1699, Personal Choice 65 at 1-888-879-4293, Select Option at 1-888-678-7009.

ABUSE DETERRENT OPIOID

Products Affected

- EMBEDA
- HYSINGLA ER
- NUCYNTA ER
- OXYCONTIN ORAL TABLET ER 12 HOUR ABUSE-DETERRENT 10 MG, 20 MG
- XTAMPZA ER
- ZOHYDRO ER ORAL CAPSULE ER 12 HOUR ABUSE-DETERRENT

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Remainder of contract year
Other Criteria	Documentation of one of the following: (1) Prior use of TWO generic opioids OR (2) BOTH of the following: (a) there is a history of or a potential for drug abuse among the individual or a member of the individual's household AND (b) documentation of current patient-prescriber opioid treatment agreement

ACTEMRA IV

Products Affected

- ACTEMRA

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	Concurrent therapy with other biological disease-modifying anti-rheumatic drugs (DMARDs)
Required Medical Information	Documentation for evaluation of active or latent Tuberculosis (TB). For new starts only: at least 2 weeks passed since administration of Herpes Zoster vaccine prior to start of therapy.
Age Restrictions	Deny if age is less than 18 years for diagnosis of RA or less than 2 years of age for diagnoses of sJIA and pJIA
Prescriber Restrictions	Deny if not prescribed by a Rheumatologist
Coverage Duration	Indefinite
Other Criteria	Subject to Part B vs Part D review and if part D is medically necessary when there is documentation of ONE of the following: (1) systemic juvenile idiopathic arthritis OR (2) polyarticular juvenile idiopathic arthritis or rheumatoid arthritis with an inadequate response to at least one disease-modifying antirheumatic drug (DMARDs) such as methotrexate

ACTEMRA SQ

Products Affected

- ACTEMRA

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	Concurrent therapy with any other biologic disease modifying anti-rheumatic drug (DMARD), e.g. tumor necrosis factor antagonists.
Required Medical Information	Documentation for evaluation of active or latent Tuberculosis (TB). For new starts only: at least 2 weeks passed since administration of Herpes Zoster vaccine prior to start of therapy.
Age Restrictions	Deny if age is less than 18 years
Prescriber Restrictions	Deny if not prescribed by a Rheumatologist
Coverage Duration	Indefinite
Other Criteria	For Polyarticular Juvenile rheumatoid arthritis, Systemic onset Juvenile chronic arthritis, and moderate to severe rheumatoid arthritis: documentation of inadequate response or inability to tolerate BOTH adalimumab (Humira) and etanercept (Enbrel) OR documentation demonstrating that a trial may be inappropriate. For Giant Cell Arteritis: documentation of inadequate response/inability to tolerate oral corticosteroids

ACTHAR HP

Products Affected

- HP ACTHAR

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	Scleroderma, osteoporosis, systemic fungal infections, ocular herpes simplex, recent surgery, history of or the presence of peptic ulcer, congestive heart failure, uncontrolled hypertension, primary adrenocortical insufficiency, adrenocortical hyperfunction, sensitivity to proteins or porcine origin, or where congenital infections are suspected in infants. OR Administration of live or live attenuated vaccines in patients receiving immunosuppressive doses of H.P. Acthar Gel. Concurrent primary adrenocortical insufficiency or adrenocortical hyperfunction.
Required Medical Information	
Age Restrictions	2 years of age or younger for diagnosis of IS, 18 years of age or older for other indications
Prescriber Restrictions	Infantile spasms: pediatric neurologist or neonatologist, all other indications: neurologist, rheumatologist, nephrologist, pulmonologist, or ophthalmologist
Coverage Duration	Infantile Spasms=1 yr All Other=1 month

PA Criteria	Criteria Details
Other Criteria	Subject to Part B vs Part D review and if part D is medically necessary when ONE of the following is present: infantile spasms OR there has been inadequate response or inability to tolerate systemic steroids (eg prednisone, methylprednisolone) and ONE of the following (1) acute exacerbation of multiple sclerosis currently receiving maintenance treatment for MS (eg Avonex, Betaseron, Copaxone, Tecfidera, etc) (2) acute exacerbation of psoriatic arthritis, rheumatoid arthritis, juvenile rheumatoid arthritis or ankylosing spondylitis currently receiving DMARD (3) nephrotic syndrome and ALL of the following (a) proteinuria greater than3.5g/ 24 hours AND (b) serum albumin less than 3 mg/dL AND (c) peripheral edema (4) systemic lupus erythematosus, systemic dermatomyositis, severe erythema multiforme, Stevens-Johnson syndrome, serum sickness, inflammatory ophthalmic disease, or symptomatic sarcoidosis

ACUTE HAE AGENTS

Products Affected

- BERINERT
- FIRAZYR
- RUCONEST

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Deny if not prescribed by an allergist or immunologist
Coverage Duration	Lifetime
Other Criteria	Subject to Part B vs Part D review and if part D is medically necessary when the following inclusion criterion is met: documentation of treatment of acute abdominal, facial or laryngeal attacks of hereditary angioedema (HAE)

ADEMPAS

Products Affected

- ADEMPAS

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	Concurrent use of phosphodiesterase inhibitors, nitrates or nitric oxide donors, pregnancy
Required Medical Information	
Age Restrictions	Deny if age is less than 18 years
Prescriber Restrictions	
Coverage Duration	6 month for initial authorization and 12 months for renewal authorizations
Other Criteria	Documentation of ONE of the following: (1) Diagnosis of pulmonary arterial hypertension (PAH) WHO Group I with New York Heart Association (NYHA) Functional Class II - IV AND (a) Diagnosis confirmed by catheterization (right-heart or Swan-Ganz) or echocardiography (b) Mean pulmonary artery pressure greater than or equal to 25 mm Hg at rest or greater than 30 mm Hg with exertion, OR (2) Diagnosis of persistent/recurrent Chronic Thromboembolic Pulmonary Hypertension (CTEPH) (WHO Group 4) after surgical treatment or inoperable CTEPH. Reauthorization criteria: Documentation of stabilization or improvement as evaluated by a cardiologist or pulmonologist.

AFREZZA

Products Affected

- AFREZZA INHALATION POWDER 12 UNIT, 4 & 8 & 12 UNIT, 4 (90) & 8 (90) UNIT, 4 UNIT, 8 UNIT

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	Deny for any of the following (1) Patient is currently a smoker or recently stopped smoking (past 6 months), (2) Patient has chronic lung diasease such as asthma of chronic obstructive pulmonary disease (3) active lung cancer or a prior history of lung cancer
Required Medical Information	Spirometry (FEV1) completed prior to initiation of therapy to idenitify potential lung disease (must provide the result)
Age Restrictions	Deny if less than 18 years
Prescriber Restrictions	
Coverage Duration	6 months for initial review and indefinite after that
Other Criteria	Afrezza is re-approved when the documentation is provided of spirometry value (FEV1) that has not declined greater than or equal to 20%

ALDURAZYME

Products Affected

- ALDURAZYME

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Indefinite
Other Criteria	Subject to Part B vs Part D review and if part D is medically necessary when there is documentation of Mucopolysaccharidosis, Type I (Hurler and Hurler-Scheie forms) and Scheie form with moderate to severe symptoms.

ALGLUCOSIDASE ALFA

Products Affected

- LUMIZYME

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Indefinite
Other Criteria	Subject to Part B vs Part D review and if part D is medically necessary in individuals with diagnosis of Pompe disease (GAA deficiency)

AMPYRA

Products Affected

- AMPYRA

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	Deny if patient has history of seizure or moderate to severe renal impairment (CrCL less than or equal to 50 mL/min)
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Remainder of contract year
Other Criteria	Diagnosis of multiple sclerosis REAUTHORIZATION CRITERIA: documentation of improvement in walking speed

ANADROL

Products Affected

- ANADROL-50

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Remainder of contract year
Other Criteria	Documentation of ONE of the following: (1) Acquired aplastic anemia (2) Anemia of chronic renal failure (3) Antineoplastic adverse reaction - Myelosuppression (4) Fanconi's anemia (5) Pure red cell aplasia OR (6) Cachexia associated with AIDS

ANDROGEL

Products Affected

- ANDROGEL
- ANDROGEL PUMP TRANSDERMAL GEL 20.25 MG/ACT (1.62%)

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	Normal prolactin level, low (morning) testosterone level [For new starts only]
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Remainder of contract year
Other Criteria	Documentation of ONE of the following (1) negative history of prostate and breast cancer OR (2) history of prostate cancer status post prostatectomy and documentation that the risk versus benefit has been assessed

ANDROGENS

Products Affected

- ANDRODERM TRANSDERMAL PATCH 24 HOUR
- FORTESTA
- STRIANT
- TESTIM
- VOGELXO PUMP
- VOGELXO TRANSDERMAL GEL 50 MG/5GM (1%)

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	Normal prolactin level, low (morning) testosterone level [For new starts only]
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Remainder of contract year
Other Criteria	Documentation of BOTH of the following: (1) inadequate response or inability to tolerate Androgel AND (2) ONE of the following (a) negative history of prostate and breast cancer OR (b) history of prostate cancer staus post prostatectomy and documentation that the risk versus benefit has been assessed

BELSOMRA

Products Affected

- BELSOMRA

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	Apply if patient is greater than or equal to 65 years
Prescriber Restrictions	
Coverage Duration	Remainder of contract year
Other Criteria	Documentation of inadequate response or inability to tolerate ramelteon (Rozerem)

BENLYSTA

Products Affected

- BENLYSTA

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Indefinite
Other Criteria	Subject to Part B vs Part D review and if part D is medically necessary when BOTH of the following are met: (1) documentation of active, autoantibody-positive, systemic lupus erythematosus (SLE) AND (2) patient is receiving concurrent treatment with at least ONE of the following: steroids, antimalarials, immunosuppressives, nonsteroidal anti-inflammatory drugs (NSAIDS)

BOTOX

Products Affected

- BOTOX

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Remainder of contract year

PA Criteria	Criteria Details
Other Criteria	Subject to Part B vs Part D review and if part D is medically necessary when there is documentation of ONE of the following diagnoses: (1) Severe primary focal hyperhidrosis (2) Blepharospasms associated with dystonia, (3) Cervical dystonia (4) adult patients with chronic migraine (at least 15 days per month with headache lasting 4 hours a day or longer) and BOTH of the following (a) an inadequate response or inability to tolerate at least 2 agents from different classes (e.g., Tricyclic antidepressants (TCAs), SNRIs or SSRIs, Anticonvulsants, Beta blockers, Calcium channel blockers) AND (b) prescribed by a neurologist (5) Overactive bladder/ Urinary incontinence with inadequate response or an inability to tolerate an anticholinergic medication (6) Strabismus AND at least one of the following: (a) diploplia, (b) abnormal head turn, (c) asthenopia, (d) impairment of peripheral vision due to esotropia (7) spasticity of limbs related to any of the following: (a) cerebral palsy, (b) demyelinating disease of CNS, (c) brain injury, (d) hemiplegia or paraplegia, (e) multiple sclerosis, (f) spinal cord injury (8) Sialorrhea (excessive drooling) due to disabling conditions such as motor neuron disease or Parkinson's disease with an inadequate response or inability to tolerate glycopyrrolate or transdermal scopolamine (9) Chronic anal fissure or anal spasm that has been unresponsive to conventional treatments (e.g steroids, nitroglycerin) (10) Focal dystonia or Spastic dystonia (11) Spasmodic dystonia or Laryngeal dystonia

BRAND ORAL FENTANYL

Products Affected

- ABSTRAL
- ACTIQ
- FENTORA BUCCAL TABLET 100 MCG, 200 MCG, 400 MCG, 600 MCG, 800 MCG
- LAZANDA
- SUBSYS SUBLINGUAL LIQUID 100 MCG, 200 MCG, 400 MCG, 600 MCG, 800 MCG

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Remainder of contract year
Other Criteria	Documentation of ALL of the following: (1) pain associated with cancer, (2) long-acting pain medication regimen, (3) member is opioid tolerant as demonstrated by adherence for one week or more of any of the following regimens: at least 25mcg of transdermal fentanyl hourly, 30mg of oxycodone daily, 60mg of oral morphine daily, 8mg of oral hydromorphone daily, 25mg of oral oxymorphone daily or an equianalgesic dose of another opioid AND (4) inadequate response to a generic oral transmucosal fentanyl citrate product

CARBAGLU

Products Affected

- CARBAGLU

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Indefinite
Other Criteria	Hyperammonemia due to the deficiency of the hepatic enzyme N-acetylglutamate synthase (NAGS)

CAYSTON

Products Affected

- CAYSTON

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	Deny if less than 7 years
Prescriber Restrictions	
Coverage Duration	Remainder of contract year
Other Criteria	Documentation of all of the following: (1) cystic fibrosis, (2) Pseudomonas Aeruginosa in the lungs, (3) Susceptibility results indicating that the Pseudomonas aeruginosa is sensitive to aztreonam AND (4) FEV1 between 25% and 75% of predicted

CERDELGA

Products Affected

- CERDELGA

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	Patient is CYP2D6 Ultra Rapid Metabolizer (URM), concurrent use of Class 1A or Class III anti-arrythmic, long QT syndrome, patient has pre-existing cardiac disease
Required Medical Information	
Age Restrictions	Deny if less than 18 years
Prescriber Restrictions	
Coverage Duration	Indefinite
Other Criteria	Diagnosis of Type 1 Gaucher disease and patient is CYP2D6 extensive metabolizer (EM), intermediate metabolizer (IM), or poor metabolizer (PM) as detected by an FDA-cleared test for determining CYP2D6 genotype

CESAMET/SANCUSO

Products Affected

- CESAMET
- SANCUSO

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Remainder of contract year
Other Criteria	Documentation of chemotherapy induced nausea and vomiting AND inadequate response to or inability to tolerate (a) ondansetron or granisetron and (b) aprepitant

CGRP ANTAGONISTS

Products Affected

- AIMOVIG 140 DOSE

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	Prescribed by or in consultation with a neurologist or headache specialist specialist certified by the United Council for Neurologic Subspecialties
Coverage Duration	6 months for initial authorization, 12 months for reauthorization
Other Criteria	Approved when ONE of the following inclusion criteria are met: (1) Diagnosis of episodic migraines defined as 4 to14 headache days per month AND inadequate response or inability to tolerate a 4 week trial of TWO of the following prophylactic medications (a) topiramate (b) divalproex sodium/ valproic acid (c) beta-blocker: metoprolol, propranolol, timolol, atenolol, nadolol (d) tricyclic antidepressants: amitriptyline, nortriptyline (e)SNRI antidepressants: venlafaxine, duloxetine OR (2) Diagnosis of chronic migraines defined as greater than or equal to 15 headache days per month AND inadequate response or inability to tolerate ONE of the following (a) a 4 week trial of TWO of the following prophylactic medications (i) topiramate (ii) divalproex sodium/ valproic acid (iii) beta-blocker: metoprolol, propranolol, timolol, atenolol, nadolol (iv) tricyclic antidepressants: amitriptyline, nortriptyline (v)SNRI antidepressants: venlafaxine, duloxetine OR (b) Inadequate response or inability to tolerate onabotulinumtoxin A (Botox) REAUTHORIZATION criteria: BOTH of the following: (1) Prescribed by or in consultation with a neurologist or headache specialist (2) Documentation of response to therapy as defined by a reduction in headache days per month (defined as at least 4 hours duration and moderate intensity)

CHOLBAM

Products Affected

- CHOLBAM

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	Deny if there is documentation of extrahepatic manifestations of bile acid synthesis disorders due to single enzyme defects or peroxisomal disorders including Zellweger spectrum disorder
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Initial criteria: 3 months. Re-authorization criteria: indefinite
Other Criteria	Documentation of One of the following: (a) Treatment of bile acid synthesis disorder due to single enzyme defect (b) Adjunctive treatment of peroxisomal disorder including Zellweger spectrum disorder in patients who exhibit manifestations of liver disease, steatorrhea, or complications from decreased fat soluble vitamin absorption. Re-authorization criteria: Documentation of improved liver function tests from the start of treatment.

CIALIS

Products Affected

- CIALIS ORAL TABLET 2.5 MG, 5 MG

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Indefinite
Other Criteria	Diagnosis of BPH and an inadequate response or inability to tolerate an alpha blocker (e.g. terazosin)

CIMZIA

Products Affected

- CIMZIA PREFILLED
- CIMZIA SUBCUTANEOUS KIT 2 X 200 MG

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	Concurrent therapy with biological DMARDs or other tumor necrosis factor antagonists
Required Medical Information	Documentation for evaluation of active or latent Tuberculosis (TB). For new starts only: at least 2 weeks passed since administration of Herpes Zoster vaccine prior to start of therapy.
Age Restrictions	Deny if less than 18 years
Prescriber Restrictions	Deny if not prescribed by a Gastroenterologist or Rheumatologist.
Coverage Duration	Indefinite
Other Criteria	Documentation of ONE of the following: (1) for diagnosis of Ankylosing Spondylitis, Psoriatic Arthritis or Rheumatoid Arthritis: inadequate response or inability to tolerate both adalimumab (Humira) AND etanercept (Enbrel) or documentation demonstrating that a trial may be inappropriate (2) for diagnosis of Crohn's Disease: inadequate response or inability to tolerate adalimumab (Humira)

CINRYZE

Products Affected

- CINRYZE
- HAEGARDA

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Deny if not prescribed by an allergist or immunologist
Coverage Duration	Indefinite
Other Criteria	Subject to Part B vs Part D review and if part D is medically necessary when ALL of the following criteria are met: (1) Diagnosis of hereditary angioedema (HAE) (2) history of laryngeal edema or airway compromise with an episode of HAE or a history of at least 2 HAE attacks per month, AND (3) inadequate response or inability to tolerate 17 alpha-alkylated androgens (e.g. danazol, oxandrolone, stanozolol) or anti-fibrinolytic agents (e.g. epsilon aminocaproic acid, tranexamic acid) for HAE prophylaxis

CORLANOR

Products Affected

- CORLANOR

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	(1) stable, symptomatic chronic heart failure (2) left ventricular ejection fraction less than or equal to 35% and (3) sinus rhythm with resting heart rate greater than or equal to 70 beats per minute
Age Restrictions	
Prescriber Restrictions	Prescribed by or in consultation with a cardiologist
Coverage Duration	Indefinite
Other Criteria	Patient is clinically stable for at least 4 weeks on an optimized and stable clinical regimen which includes: (a) maximally tolerated doses of beta blockers orinability to tolerate beta blockers, (b) ACE inhibitors or ARBs or inability to tolerate ACE inhibitor or ARB

COSENTYX

Products Affected

- COSENTYX 300 DOSE
- COSENTYX SENSOREADY 300 DOSE

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	Concurrent therapy with biological DMARDs or other tumor necrosis factor antagonists
Required Medical Information	Documentation for evaluation of active or latent Tuberculosis (TB). For new starts only: at least 2 weeks passed since administration of Herpes Zoster vaccine prior to start of therapy.
Age Restrictions	Deny if less than 18 years
Prescriber Restrictions	Deny if not prescribed by a Rheumatologist or dermatologist.
Coverage Duration	Indefinite
Other Criteria	Diagnosis of plaque psoriasis, psoriatic arthritis, or ankylosing spondylitis and inadequate response or inability to tolerate to both adalimumab (Humira) AND etanercept (Enbrel) or documentation demonstrating that a trial may be inappropriate

CRESEMBA [ORAL]

Products Affected

- CRESEMBA ORAL

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	Deny if less than 18 years
Prescriber Restrictions	prescribed by or in consultation with an infectious disease specialist
Coverage Duration	Remainder of contract year
Other Criteria	Documentation of either of the following (1) for use in the treatment of invasive aspergillosis after inadequate repsonse or inability to tolerate Voriconazole (Vfend) OR for a diagnosis of mucormycosis

CYSTARAN

Products Affected

- CYSTARAN

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Remainder of contract year
Other Criteria	Documentation of BOTH of the following: (1) diagnosis of cystinosis AND (2) patient has corneal cystine crystal accumulation

DEFERASIROX

Products Affected

- EXJADE
- JADENU
- JADENU SPRINKLE

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	CrCl less than 40 mL/min or serum creatinine more than 2 times the age-appropriate ULN, platelet counts less than 50,000/mL
Required Medical Information	Serum ferritin levels consistently greater than 300 mcg/L (as demonstrated with at least two lab values within the previous two months)
Age Restrictions	Deny if than 2 years
Prescriber Restrictions	
Coverage Duration	Initial approval=3 months, Reauthorization=6 months
Other Criteria	Documentation of ONE of the following diagnoses: (1) Chronic iron overload in nontransfusion-dependent thalassemia syndromes and all of the following: (a) patient 10 years and older (b) liver iron concentration (LIC) of at least 5 mg of iron per gram of liver dry weight (mg Fe/g dw) and (c) serum ferritin greater than 300 mcg/L OR (2) For the treatment of chronic iron overload caused by blood transfusions (transfusional hemosiderosis) in patients 2 years and older. Reauthorization criteria: One of the following: (1) Documentation of a decreased serum ferritin level compared wiht the baseline level for transfusion- dependent anemia or (2) Documentation of a decreased serum ferritin level compared with the baseline level or reduction in LIC (liver iron concentration) for Non-transfusion dependent thalssemia syndrome

DICLOFENAC 3% PRODUCTS

Products Affected

- *diclofenac sodium transdermal gel 3 %*

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	Deny if less than 18 years
Prescriber Restrictions	
Coverage Duration	90 days
Other Criteria	Documentation of diagnosis of Actinic Keratoses

DIFICID

Products Affected

- DIFICID

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	Deny if less than 18 years
Prescriber Restrictions	
Coverage Duration	10 days
Other Criteria	Documentation of the presence of Clostridium difficile-associated diarrhea confirmed by laboratory testing AND documentation of inadequate response or inability to tolerate metronidazole OR vancomycin RE-AUTHORIZATION CRITERIA: documentaton of consultation with an infectious disease specialist

DOPTELET

Products Affected

- DOPTELET ORAL TABLET 20 MG

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	Documentation of baseline platelet count less than 50,000/mcL
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 month
Other Criteria	

DUPIXENT

Products Affected

- DUPIXENT

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	Deny if less than 18 years old
Prescriber Restrictions	Deny if prescriber is not a dermatologist, allergist, immunologist
Coverage Duration	Indefinite
Other Criteria	BOTH of the following: (1) diagnosis or moderate-severe atopic dermatitis AND (2) inadequate response or inability to tolerate BOTH of the following (a) one topical steroid (medium potency or higher) AND (b) topical tacrolimus

DYSPORT

Products Affected

- DYSPORT

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Indefinite
Other Criteria	Subject to Part B vs Part D review

EGRIFTA

Products Affected

- EGRIFTA SUBCUTANEOUS SOLUTION RECONSTITUTED 1 MG

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	(1) hypothalamic-pituitary axis due to hypophysectomy, hypopituitarism, pituitary tumor/surgery, or head irradiation or trauma, (2)hypersensitivity to tesamorelin and/or mannitol, (3)malignancy, active (either newly diagnosed or recurrent) malignancies should be inactive and completely treated prior to initiating therapy, (4)pregnancy.
Required Medical Information	Waist hip ratio and waist circumference
Age Restrictions	
Prescriber Restrictions	Deny if prescriber is not a HIV-infection specialist
Coverage Duration	Remainder of contract year
Other Criteria	Patient is receiving antiretroviral therapy (ART) AND Revision of the ART regimen and weight loss efforts (dietary modification and exercise) have been ineffective in reducing the excess VAT

ELAPRASE

Products Affected

- ELAPRASE

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	Deny if age is less than 16 months
Prescriber Restrictions	
Coverage Duration	Indefinite
Other Criteria	Subject to Part B vs Part D review and if part D is medically necessary for the diagnosis of Hunter Syndrome (mucopolysaccharidosis type II [MPS II])

EMFLAZA

Products Affected

- EMFLAZA

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	Deny if less than 5 years of age
Prescriber Restrictions	Deny if not prescribed by a neurologist
Coverage Duration	Indefinite
Other Criteria	Inadequate response or inability to tolerate prednisone

EMSAM

Products Affected

- EMSAM

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	Documentation that at least 14 days has elapsed after discontinuation of antidepressants without long half-lives OR documentation at least 5 weeks has elapsed after discontinuation with antidepressants with long half-lives e.g. Fluoxetine.
Age Restrictions	Deny in patients less than 18 years of age.
Prescriber Restrictions	
Coverage Duration	Indefinite
Other Criteria	Documentation of diagnosis of major depressive disorder AND a documented inadequate response or inability to tolerate ONE SSRI or SNRI

ENBREL

Products Affected

- ENBREL SUBCUTANEOUS SOLUTION PREFILLED SYRINGE
- ENBREL SUBCUTANEOUS SOLUTION RECONSTITUTED
- ENBREL SURECLICK SUBCUTANEOUS SOLUTION AUTO-INJECTOR

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	Concurrent therapy with any other biologic disease modifying anti-rheumatic drug (DMARD), e.g. tumor necrosis factor antagonists
Required Medical Information	Documentation for evaluation of active or latent Tuberculosis (TB). For new starts only: at least 2 weeks passed since administration of Herpes Zoster vaccine prior to start of therapy.
Age Restrictions	Deny if patient is less than 2 years
Prescriber Restrictions	Deny if not prescribed by Rheumatologist or Dermatologist
Coverage Duration	Indefinite
Other Criteria	Documentation of a previous trial with infliximab (Remicade) OR ONE of the following: (1) For moderate to severe Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis or Juvenile Idiopathic Arthritis: Inadequate response or inability to tolerate ONE of the following: methotrexate, Hydroxychloroquine, Leflunomide, Azathioprine, Sulfasalazine OR (2) For moderate to severe Plaque Psoriasis: inadequate response or inability to tolerate ONE of the following drugs: Topical Calcipotriene, Topical Anthralin, Topical Steroids, Topical immunomodulators (Elidel, Protopic), Topical retinoids.

ENDARI

Products Affected

- ENDARI

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Deny if not prescribed by a hematologist or oncologist
Coverage Duration	Indefinite
Other Criteria	Member has had 2 or more painful sickle cell crises within the past 12 months

EPCLUSA

Products Affected

- EPCLUSA

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	HCV GT
Age Restrictions	Deny if less than 18 years
Prescriber Restrictions	
Coverage Duration	Duration will be applied consistent with AASLD/ IDSA guidance
Other Criteria	Criteria will be applied consistent with current AASLD/ IDSA guidance

EUCRISA

Products Affected

- EUCRISA

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	Deny if less than 2 years old
Prescriber Restrictions	
Coverage Duration	Indefinite
Other Criteria	Documentation of BOTH of the following: (1) Inadequate response to non-pharmacological interventions (i.e. use of moisturizers), (2) Inadequate response or inability to tolerate at least one of the following: (a) generic topical tacrolimus, (b) generic, prescription medium potency or higher topical steroid.

EXONDYS

Products Affected

- EXONDYS 51

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	patient has a confirmed mutation of the DMD gene that is amenable to exon 51 skipping
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Indefinite
Other Criteria	Subject to Part B vs Part D review

FABRAZYME

Products Affected

- FABRAZYME

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Indefinite
Other Criteria	Subject to Part B vs Part D review and if part D is medically necessary when there is a documentation of Fabry disease.

FENTANYL CITRATE LOZENGE

Products Affected

- *fentanyl citrate buccal*

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	Deny if less than 16 years
Prescriber Restrictions	
Coverage Duration	Remainder of contract year
Other Criteria	Documentation of all of the following: (1) pain associated with cancer, (2) long acting medication regimen AND (3) member is opioid tolerant as demonstrated by adherence to one of the following regimens for at least one week: at least 25mcg of transdermal fentanyl hourly, 30mg of oxycodone daily, 60mg of oral morphine daily, 8mg of oral hydromorphone daily, 25mg of oral oxymorphone daily or an equianalgesic dose of another opioid

FERRIPROX

Products Affected

- FERRIPROX

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	Deny if less than 18 years
Prescriber Restrictions	
Coverage Duration	Remainder of contract year
Other Criteria	Documentation of both of the following inclusion criteria: transfusional iron overload due to thalassemia syndromes AND inadequate response or inability to tolerate current chelation therapy

FLECTOR

Products Affected

- FLECTOR

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	Previously experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. Use for the treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery.
Required Medical Information	Patient had experienced treatment failure with at least 2 prescription strength oral NSAIDs or patient has a documented swallowing disorder OR has a history of peptic ulcer disease/gastrointestinal bleeding OR patient is more than 65 years of age with one additional risk factor for gastrointestinal adverse event (e.g., use of anticoagulants or chronic corticosteroids)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Remainder of contract year
Other Criteria	

FORTEO

Products Affected

- FORTEO SUBCUTANEOUS SOLUTION 600 MCG/2.4ML
- TYMLOS

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	Any of the following: (1) history of Paget's disease of the bone (2) history of bone cancer or other cancers that have metastasized to the bone (3) Skeletal malignancies or other metabolic bone disease besides osteoporosis (4) Preexisting hypercalcemia (5) Pregnant or nursing women (6) unexplained elevations of alkaline phosphatase (7) open epiphyses (8) history of external beam or implant radiation therapy involving the skeleton
Required Medical Information	Osteoporosis defined as T score of the individual's bone mineral density (BMD) is at least -2.5 standard deviations below the young adult mean OR history of osteoporotic fracture (i.e. hip, spine, etc.)
Age Restrictions	Deny if less than 18 years
Prescriber Restrictions	
Coverage Duration	Remainder of contract year
Other Criteria	Inadequate response or inability to tolerate at least one of the following (a) bisphosphonates, (b) hormone replacement therapy, (c) selective-estrogen receptor modulators (SERMs). Reauthorization criteria: documentation that cumulative lifetime therapy does not exceed 2 years

FULYZAQ

Products Affected

- MYTESI

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	Infectious diarrhea (e.g., cryptosporidiosis, C. Difficile, etc.) has been ruled out
Age Restrictions	Deny if less than 18 years
Prescriber Restrictions	
Coverage Duration	Remainder of contract year
Other Criteria	Documentation of ALL of the following: (1) diagnosis of HIV/AIDS and patient is on antiretroviral therapy (2) patient requires symptomatic relief of non-infectious diarrhea, (3) inadequate response or inability to tolerate at least one anti-diarrheal medication (e.g., loperamide, atropine/diphenoxylate, etc)

GATTEX

Products Affected

- GATTEX

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	Member left with less than 200 cm of functional small bowel
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 months
Other Criteria	Documentation of ALL of the following: (1) diagnosis of Short Bowel Syndrome AND (2) individual receives parenteral support at least three times per week. REAUTH CRITERIA: Reduction in parenteral support from baseline (prior to initiation of Gattex therapy)

GAUCHER AGENTS

Products Affected

- CEREZYME INTRAVENOUS SOLUTION RECONSTITUTED 400 UNIT
- ELELYSO
- VPRIV

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Indefinite
Other Criteria	Subject to Part B vs Part D review and if part D is medically necessary when BOTH of the following criteria are met: (1) diagnosis of Type 1 Gaucher's disease AND (2) presence of at least ONE of the following conditions: anemia, bone disease, hepatomegaly, splenomegaly or thrombocytopenia.

GOCOVRI

Products Affected

- GOCOVRI

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Prescribed by or in consultation with a neurologist
Coverage Duration	Indefinite
Other Criteria	Documentation of concurrent levodopa-based therapy

GRALISE

Products Affected

- GRALISE
- GRALISE STARTER

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Indefinite
Other Criteria	Documentation that BOTH of the following inclusion criteria are met: diagnosis of post herpetic neuralgia AND inadequate response to gabapentin

GROWTH HORMONES

Products Affected

- GENOTROPIN
- GENOTROPIN MINIQUICK
- HUMATROPE
- NORDITROPIN FLEXPRO
- NUTROPIN AQ NUSPIN 10
- NUTROPIN AQ NUSPIN 20
- NUTROPIN AQ NUSPIN 5
- OMNITROPE
- SAIZEN
- SAIZENPREP
- ZOMACTON

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	(1) Growth failure in children when all of the following inclusion criteria are met: (a) subnormal serum insulin-like growth factor-1 (IGF-1), (b) growth velocity less than or equal to 5 cm/year after 2 years of age, (c) documentation of bone age and (d) abnormal response from provocative testing, such as insulin-induced hypoglycemia test, levadopa, or clonidine. (2) Small for gestational age (SGA) with clinical documentation of no catch-up growth by 2 to 4 years of age. (3) Growth failure associated with chronic kidney disease (CKD), (4) Growth failure associated with Noonan Syndrome, Prader-Willi Syndrome, Turner Syndrome or short stature homeobox-containing gene (SHOX) deficiency, (5) Diagnostically confirmed Growth hormone deficiency in adults OR (6) Idiopathic short stature defined by height standard deviation score (SDS) less than or equal to 2.25 and documentation of growth velocity
Age Restrictions	
Prescriber Restrictions	Recommendation by an endocrinologist or nephrologist
Coverage Duration	12 months

PA Criteria	Criteria Details
Other Criteria	REAUTHORIZATION for additional 12 months: Annual clinical re-evaluation by the treating endocrinologist AND one of the following criteria is met: (1) for Growth failure in children - normalization of IGF-1 (2) for Small for gestational age (SGA) - increase in growth velocity from baseline (3) for Growth failure associated with chronic kidney disease (CKD) - no history of renal transplant (4) for Growth failure associated with Noonan Syndrome, Prader-Willi, Turner Syndrome OR SHOX - documentation of clinical reevaluation by endocrinologist (5) for Growth hormone deficiency in adults - normalization of IGF-1: OR (6) Idiopathic short stature - increase in growth velocity from baseline

HARVONI

Products Affected

- HARVONI

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	Hepatitis C Genotype
Age Restrictions	Deny if less than 12 years
Prescriber Restrictions	
Coverage Duration	Duration will be applied consistent with AASLD/ IDSA guidance
Other Criteria	Criteria will be applied consistent with current AASLD/ IDSA guidance

HEPATITIS C AGENTS

Products Affected

- DAKLINZA
- SOVALDI
- TECHNIVIE
- VIEKIRA PAK
- VIEKIRA XR
- VOSEVI
- ZEPATIER

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	Hepatitis C Genotype
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Duration will be applied consistent with AASLD/ IDSA guidance
Other Criteria	BOTH of the following (1) criteria will be applied consistent with current AASLD/IDSA guidance and (2) inability to tolerate Harvoni, Epclusa, or Mavyret where indicated.

HETLIOZ

Products Affected

- HETLIOZ

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Deny if not prescribed by a sleep specialist or neurologist
Coverage Duration	Remainder of contract year
Other Criteria	Diagnosis of a circadian period greater than 24 hours

HIGH DOSE OPIOIDS

Products Affected

- BELBUCA BUCCAL FILM 300 MCG, 450 MCG, 600 MCG, 750 MCG, 900 MCG
- DILAUDID ORAL TABLET 4 MG, 8 MG
- DOLOPHINE
- DURAGESIC-100
- DURAGESIC-25
- DURAGESIC-50
- DURAGESIC-75
- EMBEDA
- EXALGO ORAL TABLET ER 24 HOUR ABUSE-DETERRENT
- *fentanyl transdermal patch 72 hour 100 mcg/hr, 25 mcg/hr, 37.5 mcg/hr, 50 mcg/hr, 62.5 mcg/hr, 75 mcg/hr, 87.5 mcg/hr*
- *hydromorphone hcl er*
- *hydromorphone hcl oral tablet 4 mg, 8 mg*
- HYSINGLA ER
- KADIAN ORAL CAPSULE EXTENDED RELEASE 24 HOUR 100 MG, 200 MG, 80 MG
- *methadone hcl oral solution*
- *methadone hcl oral tablet*
- *morphine sulfate er beads oral capsule extended release 24 hour 120 mg*
- *morphine sulfate er oral capsule extended release 24 hour 100 mg, 60 mg, 80 mg*
- *morphine sulfate er oral tablet extended release 100 mg, 200 mg, 60 mg*
- MS CONTIN ORAL TABLET EXTENDED RELEASE 100 MG, 200 MG, 60 MG
- NUCYNTA ER
- NUCYNTA ORAL TABLET 100 MG, 75 MG
- OPANA ORAL TABLET 10 MG
- *oxycodone hcl er oral tablet er 12 hour abuse-deterrent 30 mg, 40 mg, 60 mg, 80 mg*
- *oxycodone hcl oral tablet 30 mg*
- OXYCONTIN ORAL TABLET ER 12 HOUR ABUSE-DETERRENT 30 MG, 40 MG, 60 MG, 80 MG
- *oxymorphone hcl er oral tablet extended release 12 hour 20 mg, 30 mg, 40 mg*
- *oxymorphone hcl oral tablet 10 mg*
- ROXICODONE ORAL TABLET 30 MG
- XTAMPZA ER

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Remainder of contract year

PA Criteria	Criteria Details
Other Criteria	NEW TO HIGH DOSE OPIOID THERAPY (morphine equivalent dose 90mg per day or greater): ONE of the following (A) pain associated with cancer OR (B) chronic non-cancer pain and BOTH of the following (1) member is opioid tolerant (e.g at least one week where total daily dose is at least one of the following: 30mg of oxycodone, 60mg of oral morphine, 8mg of oral hydromorphone, 25mg of oral oxymorphone or an equianalgesic dose of another opioid) AND (2) the member has been evaluated for non-opioid prescription pharmacologic treatment prior to initiation of high dose opioid therapy. CONTINUING HIGH DOSE OPIOID THERAPY (morphine equivalent dose 90mg per day or greater): ONE of the following (1) pain associated with cancer OR (2) chronic non-cancer pain and ALL (a) member's pain has been assessed within the last 6 months AND (b) member is tolerating medication appropriately AND (c) member has improved functioning AND (d) member is not being treated for substance abuse

HOMOZYGOUS FAMILIAL HYPERCHOLESEROLEMIA AGENTS

Products Affected

- JUXTAPID
- KYNAMRO SUBCUTANEOUS SOLUTION PREFILLED SYRINGE

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	Kynamro and Jutaxapid: Moderate-severe liver impairment, active liver disease, unexplained LFT abnormalities. Juxtapid: Pregnancy, concomitant use with strong or moderate CYP3A4 inhibitors.
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 months
Other Criteria	Documentation of BOTH of the following: (1) diagnosis of Homozygous Familial Hypercholesterolemia with ONE of the following: (a) Genetic confirmation of 2 mutant alleles at the LDL receptor. Apo B, PCSK9, or ARH adaptor protein gene locus (b) Untreated LDL-C greater than 500 mg/dL or treated LDL cholesterol greater than or equal to 300 mg/dL or treated non-HDL cholesterol greater than or equal to 330 mg/dL together with either of the following: (i) Cutaneous or tendonous xanthoma prior to 10 years of age (ii) Elevated LDL cholesterol prior to lipid-lowering therapy consistent with HeFH in both parents AND (2) Inadequate response or inability to tolerate the combination of ONE high potency statin at the maximally tolerated dose (e.g., atorvastatin, rosuvastatin) with either ezetimibe or a Bile Acid Sequestrant (e.g. cholestyramine). REAUTHORIZATION CRITERIA: Documentation of reduction in LDL level since initiation of therapy with respective drug

HORIZANT

Products Affected

- HORIZANT ORAL TABLET EXTENDED RELEASE

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Indefinite
Other Criteria	Diagnosis of (1) Postherpetic neuralgia and inadequate response or inability to tolerate gabapentin OR (2) restless legs syndrome and inadequate response or inability to tolerate pramipexole or ropinerole

HRM

Products Affected

- ALLZITAL
- ASCOMP-CODEINE
- BENTYL INTRAMUSCULAR
- *benztropine mesylate injection*
- *benztropine mesylate oral*
- BUPAP ORAL TABLET 50-300 MG
- *butalbital-acetaminophen oral tablet*
- *butalbital-apap-caff-cod*
- *butalbital-apap-caffeine oral capsule*
- *butalbital-apap-caffeine oral tablet 50-325-40 mg*
- *butalbital-asa-caff-codeine*
- *butalbital-aspirin-caffeine oral capsule*
- *carbinoxamine maleate oral solution*
- *carbinoxamine maleate oral tablet 4 mg*
- *chlordiazepoxide hcl*
- *chlorzoxazone oral tablet 500 mg*
- *clemastine fumarate oral tablet 2.68 mg*
- COGENTIN
- DEMEROL INJECTION SOLUTION 25 MG/ML, 50 MG/ML
- *dicyclomine hcl intramuscular*
- *dicyclomine hcl oral*
- DIGITEK ORAL TABLET 250 MCG
- DIGOX ORAL TABLET 250 MCG
- *digoxin injection*
- *digoxin oral tablet 250 mcg*
- *dipyridamole oral*
- *ergoloid mesylates oral*
- ESGIC ORAL TABLET
- FIORICET ORAL CAPSULE
- FIORICET/CODEINE ORAL CAPSULE 50-300-40-30 MG
- FIORINAL
- FIORINAL/CODEINE #3
- *flurazepam hcl*
- *hydroxyzine hcl intramuscular*
- *hydroxyzine hcl oral syrup*
- *hydroxyzine hcl oral tablet*
- *hydroxyzine pamoate oral*
- INDOCIN ORAL
- *indomethacin er*
- *indomethacin oral*
- KARBINAL ER ORAL SUSPENSION EXTENDED RELEASE
- LANOXIN INJECTION SOLUTION 0.25 MG/ML
- LANOXIN ORAL TABLET 250 MCG
- LORZONE
- *meperidine hcl injection solution 100 mg/ml, 25 mg/ml, 50 mg/ml*
- *meperidine hcl oral*
- *meprobamate*
- METAXALL
- *metaxalone*
- *methocarbamol injection solution 1000 mg/10ml*
- *methocarbamol oral*
- *orphenadrine citrate er*
- *orphenadrine citrate injection*
- *pentazocine-naloxone hcl*
- PHENADOZ RECTAL SUPPOSITORY 12.5 MG
- PHENERGAN INJECTION
- PHRENILIN FORTE ORAL CAPSULE 50-300-40 MG
- *promethazine hcl injection*
- *promethazine hcl oral syrup*
- *promethazine hcl oral tablet*
- *promethazine hcl rectal*
- *promethazine vc plain oral solution*
- PROMETHEGAN RECTAL SUPPOSITORY 25 MG, 50 MG
- ROBAXIN INJECTION SOLUTION 1000 MG/10ML
- RYVENT
- SKELAXIN
- TENCON ORAL TABLET 50-325 MG
- TIVORBEX
- *trihexyphenidyl hcl*
- VANATOL LQ
- VISTARIL
- ZEBUTAL ORAL CAPSULE 50-325-40 MG

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	Apply if patient is greater than or equal to 65 years
Prescriber Restrictions	
Coverage Duration	Remainder of contract year
Other Criteria	Documentation that the risk versus benefit has been assessed for this request of a high risk medication (HRM) in elderly

HRM ESTROGENS

Products Affected

- ACTIVELLA
- ALORA
- AMABELZ
- ANGELIQ
- CLIMARA
- CLIMARA PRO
- COMBIPATCH
- DIVIGEL TRANSDERMAL GEL 1 MG/GM
- ELESTRIN
- ESTRACE ORAL
- *estradiol oral*
- *estradiol transdermal*
- *estradiol-norethindrone acet*
- EVAMIST
- FEMHRT LOW DOSE
- FYAVOLV
- JINTELI
- MENOSTAR
- MIMVEY
- MIMVEY LO
- MINIVELLE
- *norethindrone-eth estradiol*
- PREFEST
- PREMARIN INJECTION
- PREMARIN ORAL
- VIVELLE-DOT

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	Apply if patient is greater than or equal to 65 years
Prescriber Restrictions	
Coverage Duration	Remainder of contract year
Other Criteria	Documentation of ONE of the following: (1) Inadequate response or inability to tolerate vaginal estrogen preparations (e.g. vaginal tablets, rings, or cream, etc) OR (2) Documentation that the risk versus benefit has been assessed for this request of a high risk medication (HRM) in elderly

HRM KETOROLAC

Products Affected

- *ketorolac tromethamine injection solution 15 mg/ml, 30 mg/ml*
- *ketorolac tromethamine intramuscular solution 60 mg/2ml*
- *ketorolac tromethamine oral*

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	Apply if patient is greater than or equal to 65 years
Prescriber Restrictions	
Coverage Duration	One Month
Other Criteria	Documentation of ONE of the following: (1) Inadequate response or inability to tolerate TWO alternative NSAIDs such as meloxicam, naproxen, celecoxib, ibuprofen, etc. OR (2) Documentation that the risk versus benefit has been assessed for this request of a high risk medication (HRM) in elderly

HRM LONG ACTING SULFONYLUREAS

Products Affected

- *chlorpropamide*
- *glyburide micronized*
- *glyburide oral*
- *glyburide-metformin*
- GLYNASE

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	Apply if patient is greater than or equal to 65 years
Prescriber Restrictions	
Coverage Duration	Remainder of contract year
Other Criteria	Documentation of ONE of the following: (1) Inadequate response or inability to tolerate glipizide and glimepiride OR (2) Documentation that the risk versus benefit has been assessed for this request of a high risk medication (HRM) in elderly

HRM NON BENZODIAZEPINE HYPNOTICS

Products Affected

- AMBIEN
- AMBIEN CR
- EDLUAR
- *eszopiclone*
- INTERMEZZO
- LUNESTA
- SONATA
- *zaleplon*
- *zolpidem tartrate*
- *zolpidem tartrate er*

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	Apply if patient is greater than or equal to 65 years
Prescriber Restrictions	
Coverage Duration	3 months for initial authorization, end of contract year for reauthorization
Other Criteria	Documentation of ONE of the following: (1) Inadequate response or inability to tolerate ramelteon (Rozerem) OR (2) Documentation that the risk versus benefit has been assessed for this request of a high risk medication (HRM) in elderly REAUTHORIZATION CRITERIA: documentation that prescriber is aware of the risk versus benefit of using the medication chronically (greater than 90 days)

HRM SHORT TERM SKELETAL MUSCLE RELAXANTS

Products Affected

- AMRIX
- *carisoprodol oral*
- *carisoprodol-aspirin*
- *carisoprodol-aspirin-codeine*
- *cyclobenzaprine hcl oral*
- FEXMID
- SOMA

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	Apply if patient is greater than or equal to 65 years
Prescriber Restrictions	
Coverage Duration	3 weeks
Other Criteria	Documentation that the risk versus benefit has been assessed for this request of a high risk medication (HRM) in the elderly

HRM TCAS

Products Affected

- *amitriptyline hcl oral*
- ANAFRANIL
- *chlordiazepoxide-amitriptyline*
- *clomipramine hcl oral*
- *doxepin hcl oral*
- *imipramine hcl oral*
- *imipramine pamoate*
- *nortriptyline hcl oral*
- PAMELOR ORAL CAPSULE
- *perphenazine-amitriptyline*
- SURMONTIL
- *trimipramine maleate oral*

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	Apply if patient is greater than or equal to 65 years
Prescriber Restrictions	
Coverage Duration	Remainder of contract year
Other Criteria	Documentation of ONE of the following: (1) Inadequate response or inability to tolerate one generic SSRI (e.g. sertraline, fluoxetine, etc) or one generic SNRI (e.g. duloxetine, venlafaxine) OR (2) Documentation that the risk versus benefit has been assessed for this request of a high risk medication (HRM) in elderly

HUMIRA

Products Affected

- HUMIRA PEDIATRIC CROHNS START SUBCUTANEOUS PREFILLED SYRINGE KIT 40 MG/0.8ML, 80 MG/0.8ML, 80 MG/0.8ML & 40MG/0.4ML
- HUMIRA PEN SUBCUTANEOUS PEN-INJECTOR KIT
- HUMIRA PEN-CD/UC/HS STARTER
- HUMIRA PEN-PS/UV STARTER
- HUMIRA SUBCUTANEOUS PREFILLED SYRINGE KIT

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	Concurrent therapy with any other biologic disease modifying anti-rheumatic drug (DMARD), e.g. tumor necrosis factor antagonists
Required Medical Information	Documentation for evaluation of active or latent Tuberculosis (TB). For new starts only: at least 2 weeks passed since administration of Herpes Zoster vaccine prior to start of therapy.
Age Restrictions	Deny if less than 2 years for JIA, less than 6 years for Crohn's disease, less than 18 years for all other indications
Prescriber Restrictions	Deny if not prescribed by a Rheumatologist, Dermatologist, Ophthalmologist or Gastroenterologist accordingly
Coverage Duration	Indefinite
Other Criteria	Documentation of a previous trial with infliximab (Remicade) OR ONE of the following: (1) For moderate to severe Rheumatoid Arthritis, Ankylosing Spondylitis, moderate to severe Juvenile Idiopathic Arthritis (JIA) , or Psoriatic Arthritis: inadequate response or inability to tolerate ONE of the following: methotrexate, hydroxychloroquine, leflunomide, azathioprine, sulfasalazine, (2) For moderate to severe Plaque Psoriasis: inadequate response or inability to tolerate ONE of the following drugs: topical calcipotriene containing products, topical anthralin, topical steroids, topical immunomodulators (Elidel, Protopic), topical retinoids (3) For Crohn's Disease or Ulcerative Colitis: inadequate response or inability to tolerate ONE of the following: corticosteroid, Aminosalicylate, or Immunomodulators (ex. azathioprine or 6-mercaptopurine), (4) diagnosis of Hidradenitis suppurativa OR (5) diagnosis of non-infectious intermediate, posterior, or pan- uveitis and inadequate response or inability to tolerate BOTH of the following (1) ONE topical ophthalmic steroid AND (2) ONE oral corticosteroid

HUMULIN U500

Products Affected

- HUMULIN R U-500 (CONCENTRATED)
- HUMULIN R U-500 KWIKPEN SUBCUTANEOUS SOLUTION PEN-INJECTOR

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Deny if not prescribed by an endocrinologist
Coverage Duration	Indefinite
Other Criteria	Documentation of BOTH of the following (1) diagnosis of type 1 or type 2 diabetes mellitus AND (2) insulin requirement exceeding 200 units per day

ILARIS

Products Affected

- ILARIS SUBCUTANEOUS SOLUTION

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	Deny if less than 2 years for SJIA, less than 4 years for other indications
Prescriber Restrictions	
Coverage Duration	Indefinite
Other Criteria	Subject to Part B vs Part D review and if part D is medically necessary for ONE of the following diagnosis: (1) cryopyrin-associated periodic syndromes [CAPS], (2) systemic juvenile idiopathic arthritis, (3) Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS), (4) Hyperimmunoglobulin D Syndrome (HIDS) /Mevalonate Kinase Deficiency (MKD) , (5) Familial Mediterranean Fever (FMF)

INCRELEX

Products Affected

- INCRELEX

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	Known or suspected malignancy, closed epiphyses
Required Medical Information	
Age Restrictions	Deny if less than 2 years
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	Diagnosis of ONE of the following: (1) growth hormone gene deletion who have developed neutralizing antibodies to growth hormone OR (2) Severe primary IGF-1 deficiency and ALL of the following (a) height standard deviation score less than or equal to -3.0 AND (b) basal IGF-1 standard deviation score less than or equal to -3.0 AND normal or elevated growth hormone REAUTHORIZATION: documentation of increase in growth velocity from baseline AND annual clinical re-evaluation by the treating endocrinologist

INFLIXIMAB

Products Affected

- INFLECTRA
- REMICADE
- RENFLEXIS

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	Concurrent therapy with biological DMARDs or other tumor necrosis factor antagonists
Required Medical Information	Documentation for evaluation of active or latent Tuberculosis (TB)
Age Restrictions	For Crohn's disease and Ulcerative Colitis: deny if less than 6 years, For Polyarticular Juvenile Idiopathic Arthritis (PJIA): deny if less than 4 year of age, For all other diagnosis: deny if less than 18 years of age.
Prescriber Restrictions	
Coverage Duration	Indefinite

PA Criteria	Criteria Details
Other Criteria	Subject to Part B vs Part D review and if part D is medically necessary for the diagnoses of: (1) active, moderate to severe ankylosing spondylitis and an inadequate response or inability to tolerate at least one other treatment such as NSAIDs, COX2 inhibitors, or methotrexate (2) moderate to severe ulcerative colitis or Crohn's disease and an inadequate response or inability to tolerate at least one conventional treatment e.g corticosteroids, aminosalicylates, immunomodulators (3) chronic, severe (i.e. extensive and/or disabling) plaque psoriasis for individuals who are candidates for systemic therapy and have had an inadequate response or are unable to tolerate other systemic therapies (4) Rheumatoid arthritis in combination with methotrexate or as monotherapy when the individual is intolerant of or has a contraindication to methotrexate and inadequate response to any DMARD (eg sulfasalazine, azathioprine, cyclophosphamide, cyclosporine, methotrexate, other anti-tumor necrosis factor agents) (5) active psoriatic arthritis and inability to tolerate or inadequate response to at least one DMARD (6) Wegener's granulomatosis with evidence of severe active disease and inadequate response or inability to tolerate corticosteroids and immunosuppressant agents (7) Chronic Pulmonary Sarcoidosis with a documentation of failure or intolerance to 3-month trial of corticosteroids and immunosuppressive agents (8) Ulcerative Colitis in Children who have moderate to severe active UC and who have had an inadequate response to conventional therapies (9) Pyoderma gangrenosum (10) Polyarticular juvenile idiopathic arthritis (JIA) with evidence of active disease and who have had a documented failure or intolerance to a 3-month trial of any of the FDA-approved biologic DMARD

INGREZZA

Products Affected

- INGREZZA

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Prescribed by or in consultation with a neurologist or a psychiatrist
Coverage Duration	Initial authorization: 3 months, Reauthorization: indefinite
Other Criteria	Diagnosis of moderate to severe tardive dyskinesia and (1) one of the following: (a) persistent symptoms of tardive dyskinesia despite a trial of dose reduction, tapering, or discontinuation of the offending medication, or (b) member is not a candidate for a trial of dose reduction, tapering, or discontinuation of the offending medication. Reauthorization criteria: Valbenazine (Ingrezza) is reapproved with documentation of positive clinical response to Ingrezza therapy

INHALED TOBRAMYCIN

Products Affected

- TOBI PODHALER

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	6 years of age or older
Prescriber Restrictions	
Coverage Duration	Indefinite
Other Criteria	(1) diagnosis of cystic fibrosis AND (2) evidence of P. aeruginosa in the lungs

INJECTABLE METHOTREXATE

Products Affected

- OTREXUP SUBCUTANEOUS SOLUTION AUTO-INJECTOR 10 MG/0.4ML, 12.5 MG/0.4ML, 15 MG/0.4ML, 17.5 MG/0.4ML, 20 MG/0.4ML, 22.5 MG/0.4ML, 25 MG/0.4ML
- RASUVO SUBCUTANEOUS SOLUTION AUTO-INJECTOR 10 MG/0.2ML, 12.5 MG/0.25ML, 15 MG/0.3ML, 17.5 MG/0.35ML, 20 MG/0.4ML, 22.5 MG/0.45ML, 25 MG/0.5ML, 30 MG/0.6ML, 7.5 MG/0.15ML

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	Psoriasis: deny if less than 18 years
Prescriber Restrictions	RA and pJIA: Recommended by rheumatologist. Psoriasis: recommended by dermatologist
Coverage Duration	Indefinite
Other Criteria	Injectable Methotrexate is approved when ONE of the following is met: (1) Diagnosis of severe, active rheumatoid arthritis (RA), psoriatic arthritis or polyarticular juvenile idiopathic arthritis (pJIA) and inadequate response or inability to tolerate oral methotrexate OR (2) diagnosis of severe psoriasis and an inadequate response to BOTH of the following (a) oral methotrexate AND (b) topical steroids (e.g. clobetasol propionate cream/ointment, betamethasone cream/ointment, etc.)

INTRAVENOUS IMMUNE GLOBULIN (IVIG)

Products Affected

- BIVIGAM INTRAVENOUS SOLUTION 10 GM/100ML
- CARIMUNE NF INTRAVENOUS SOLUTION RECONSTITUTED 6 GM
- FLEBOGAMMA DIF INTRAVENOUS SOLUTION 5 GM/50ML
- GAMMAGARD INJECTION SOLUTION 2.5 GM/25ML
- GAMMAGARD S/D LESS IGA
- GAMMAKED INJECTION SOLUTION 1 GM/10ML
- GAMMAPLEX INTRAVENOUS SOLUTION 10 GM/100ML, 10 GM/200ML, 20 GM/200ML, 5 GM/50ML
- GAMUNEX-C INJECTION SOLUTION 1 GM/10ML
- OCTAGAM INTRAVENOUS SOLUTION 1 GM/20ML, 2 GM/20ML
- PRIVIGEN INTRAVENOUS SOLUTION 20 GM/200ML

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	primary immune deficiency disease(eg congenital hypogammaglobulinemia, immunodeficiency with increased IGM, common variable immunodeficiency Wiskott-Aldrich Syndrome, combined immunity deficiency)
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 months

PA Criteria	Criteria Details
Other Criteria	Subject to Part B vs Part D review and if Part D is medically necessary when ONE of the following is present (1) autoimmune mucocutaneous blistering disease pemphigus vulgaris, pemphigus foliaceus, bullous pemphigoid, mucous membrane (cicatricial) pemphigoid , benign mucous membrane pemphigoid, epidermolysis bullosa acquisita and ONE of the following: (a) inadequate response or inability to tolerate conventional therapy (ie steroids, immunosuppressants) OR (b) rapidly progressive disease in conjunction with conventional therapy (ie steroids, immunosuppressants) (2) Erythema multiforme major (SJS, TEN) and SCORTEN level 3 or greater (3) scleromyxedema (4) acute idiopathic thrombocytopenia purpura (ITP) and ONE of the following (a) management of acute bleeding (b) used to increase platelet count prior to surgical procedures) (c) severe thrombocytopenia (platelets less than 20, 000 per uL) or (d) high risk for intracerebral hemorrhage (5) chronic ITP and ALL of the following (a) inadequate response or inability to tolerate corticosteroids (b) duration of illness greater than 6 months (c) platelets persistently less than 20,000/ uL (6) chronic B-cell lymphocytic leukemia with IgG less than 600mg/dL and recurrent, serious bacterial infections requiring antibiotic therapy (7) hematopoetic stem cell transplant and IgG less than 400mg/dL (8) HIV and all of the following (a) less than 14 years of age (b) evidence of qualitative or quantitative humoral immunologic defects and (c) current bacterial infection despite antimicrobial prophylaxis (9) solid organ transplant (10) chronic inflammatory demyelinating polyneuritis confirmed by electrodiagnostic testing or nerve biopsy and an inadequate response or inability to tolerate corticosteroids (11) dermatomyositis or polymyositis diagnosed by laboratory testing (antinuclear or myositis specific antibodies), biopsy, EMG, or MRI) and inadequate response or inability to tolerate steroids or immunosuppressants (12) Guillain Barre syndrome with impaired function (ie unable to stand or walk without aid) (13) Lambert Eaton myasthenic syndrome refractory to steroids, immunosuppressants, or cholinesterase inhibitors (14) multifocal motor neuropathy diagnosed by electrodiagnostic studies (15) acute exacerbations of MS unresponsive to steroids (16) myasthenia gravis refractory to at least 8 weeks of standard therapy (steroids, immunosupressants, cholinesterase inhibitors) (17) myasthenic crisis (18) stiff person syndrome refractory to standard therapy (muscle relaxants, benzodiazepines, gabapentin) (19)
	severe, active SLE unresponsive to steroids (20) Kawasaki disease CONTINUATION OF THERAPY CRITERIA: Documentation of clinical improvement using objective monitoring as appropriate to the diagnosis such as, but not limited to, Rankin score and Activities of Daily Living (ADL) scores.

JYNARQUE

Products Affected

- JYNARQUE

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	Baseline serum transaminases and bilirubin prior to initiation of therapy
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	Deny if not prescribed by a nephrologist or kidney transplant specialist
Coverage Duration	3 months for initial and 12 months for re-authorization
Other Criteria	RE-AUTHORIZATION: ALL of the following (1) ONE of the following (a) decline in kidney function has slowed or (b) kidney pain has improved and (2) serum transaminase less than 3 times the upper limit of normal and (3) bilirubin less than 2 times upper limit of normal

KALYDECO

Products Affected

- KALYDECO

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	Patients with cystic fibrosis who are homozygous for the F508del mutation in the CFTR
Required Medical Information	
Age Restrictions	Deny if age less than 2 years for granules and less than 6 years of age for tablets
Prescriber Restrictions	
Coverage Duration	Indefinite
Other Criteria	Diagnosis of Cystic Fibrosis with documentation of one mutation in the CFTR gene that is responsive to ivacaftor based on clinical and/or in vitro assay data.

KANUMA

Products Affected

- KANUMA

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Initial authorization: 3 month, Re-authorization: end of contract year
Other Criteria	Diagnosis of Lysosomal acid lipase (LAL) deficiency (also known as Wolman disease and cholesteryl ester storage disease [CESD]). Reauthorization criteria: Patient is responding to the medication as indicated by improvement in ALT/AST values, Serum lipid levels (LDL-C, non-HDL, TGs, HDL), hepatic fat content, organ volumes

KEVEYIS

Products Affected

- KEVEYIS

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	Concomittant use of high dose Aspirin, severe pulmonary disease and hepatic insufficiency
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Initial criteria: 2 months Reauthorization: indefinite
Other Criteria	Reauthorization Criteria: Dichlorphenamide (Keveyis) is reapproved with documentation that prescriber has evaluated the patient's response to dichlorphenamide and recommends continuation of the treatment

KEVZARA

Products Affected

- KEVZARA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D.
Exclusion Criteria	Concurrent therapy with any other biologic disease modifying anti-rheumatic drug (DMARD), e.g. tumor necrosis factor antagonists
Required Medical Information	Documentation for evaluation of active or latent Tuberculosis (TB). For new starts only: at least 2 weeks passed since administration of live vaccines prior to start of therapy
Age Restrictions	Deny if less than 18 years
Prescriber Restrictions	Deny if not prescribed by rheumatologist
Coverage Duration	Indefinite
Other Criteria	Rheumatoid arthritis: BOTH of the following (1) inadequate response or inability to tolerate to both adalimumab (Humira) AND etanercept (Enbrel) or documentation demonstrating that a trial may be inappropriate

KINERET

Products Affected

- KINERET SUBCUTANEOUS SOLUTION PREFILLED SYRINGE

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	Concurrent therapy with any other biologic disease modifying anti-rheumatic drug (DMARD), e.g. tumor necrosis factor antagonists
Required Medical Information	Documentation for evaluation of active or latent Tuberculosis (TB)
Age Restrictions	
Prescriber Restrictions	Deny if not prescribed by rheumatologist or pediatric specialist
Coverage Duration	Indefinite
Other Criteria	For diagnosis of Rheumatoid Arthritis or Juvenile idiopathic arthritis: inadequate response or inability to tolerate to both adalimumab (Humira) AND etanercept (Enbrel)

KORLYM

Products Affected

- KORLYM

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	Pregnancy
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Indefinite
Other Criteria	Documentation of ALL of the following: (1) hyperglycemia secondary to hypercortisolism in adult patient with endogenous Cushing syndrome, (2) patient has type 2 diabetes mellitus or glucose intolerance AND (3) patient has failed surgery or is not a candidate for surgery.

LIDOCAINE TRANSDERMAL PATCH

Products Affected

- *lidocaine external patch 5 %*
- LIDODERM

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Indefinite
Other Criteria	Documentation of post-herpetic neuralgia or diabetic peripheral neuropathy

LYRICA

Products Affected

- LYRICA
- LYRICA CR

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	Deny if less than 18 years
Prescriber Restrictions	
Coverage Duration	Indefinite
Other Criteria	Documentation of ONE of the following: (1) a diagnosis of either: (a) neuropathic pain associated with diabetic peripheral neuropathy, (b) neuropathic pain associated with spinal cord injury or (c) fibromyalgia and inadequate response or inability to tolerate duloxetine OR (2) an inadequate response or inability to tolerate gabapentin and documentation of a diagnosis of either of the following: (a) partial-onset epileptic seizures or (b) post-herpetic neuralgia

MAKENA

Products Affected

- MAKENA

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Remainder of contract year
Other Criteria	Subject to Part B vs Part D review and if part D is medically necessary in individuals at risk of preterm birth when ALL of the following are met: (1) singleton pregnancy (2) not currently in preterm labor (3) there are no other risk factors for preterm birth (such as pregnancy induced hypertension) (4) documented history of singleton spontaneous preterm birth (occurring less than 37 weeks gestation) AND (5) gestational age is between 16 weeks and 37 weeks.

MAVYRET

Products Affected

- MAVYRET

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	Hepatitis C Genotype
Age Restrictions	Deny if less than 18 years
Prescriber Restrictions	
Coverage Duration	Duration will be applied consistent with AASLD/IDSA guidance
Other Criteria	Criteria will be applied consistent with current AASLD/IDSA guidance

MODAFINIL

Products Affected

- *modafinil*

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	For NARCOLEPSY or SHIFT WORK DISORDER: Recommended by a neurologist or sleep specialist
Coverage Duration	Indefinite
Other Criteria	FOR NARCOLEPSY: Documentation of a diagnosis of Narcolepsy. FOR OBSTRUCTIVE SLEEP APNEA/HYPOPNEA SYNDROME (OSAHS): Documentation that the medication is being used as an adjunct treatment for the underlying obstruction. FOR SHIFT WORK SLEEP DISORDER (SWSD): Documentation that the member has no medical or mental disorder accounting for the symptoms AND the symptoms do not meet criteria for any other sleep disorder producing insomnia or excessive sleepiness (e.g. time-zone change [jet lag] syndrome)

MOZOBIL

Products Affected

- MOZOBIL

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Remainder of contract year
Other Criteria	Documentation of use in combination with a granulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in individuals who have ONE of the following conditions: (1) Non-Hodgkin's lymphoma OR (2) Multiple myeloma

MULTIPLE SCLEROSIS AGENTS

Products Affected

- AUBAGIO
- GILENYA ORAL CAPSULE 0.5 MG

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Indefinite
Other Criteria	ONE of the following: (1) inadequate response or inability to tolerate ONE of the following (a) Avonex, (b) Plegridy (c) Betaseron (d) Copaxone (e) Glatopa OR (f) Tecfidera OR (2) continuation of therapy with requested agent

MYALEPT

Products Affected

- MYALEPT

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Indefinite
Other Criteria	

NATPARA

Products Affected

- NATPARA

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	Deny if patient has a diagnosis of hypoparathyroidism caused by calcium-sensing receptor mutations or post-surgical hypoparathyroidism
Required Medical Information	
Age Restrictions	Deny if age less than 18 years
Prescriber Restrictions	
Coverage Duration	Indefinite
Other Criteria	

NON ORAL PAH AGENTS

Products Affected

- VENTAVIS

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Deny if not prescribed by Cardiologist or Pulmonologist
Coverage Duration	6 months for initial approvals and 12 months for renewals
Other Criteria	Subject to Part B vs Part D review and if part D is medically necessary when ALL of the following are met: (1) Documentation of a diagnosis of pulmonary arterial hypertension (PAH) WHO Group I with New York Heart Association (NYHA) Functional Class II to IV (2) Diagnosis confirmed by catheterization (right-heart or Swan-Ganz) or echocardiography (3) Documentation of mean pulmonary artery pressure greater than or equal to 25 mm Hg at rest or greater than 30 mm Hg with exertion. RE-AUTHORIZATION CRITERIA: Documentation of stabilization or improvement as evaluated by a cardiologist or pulmonologist.

NON-ORAL ANTIBIOTICS

Products Affected

- AVYCAZ
- CUBICIN
- DALVANCE
- *daptomycin intravenous solution reconstituted 500 mg*
- *linezolid intravenous solution 600 mg/300ml*
- ORBACTIV
- SIVEXTRO
- SYNERCID
- TEFLARO
- VABOMERE
- ZERBAXA
- ZYVOX INTRAVENOUS SOLUTION 600 MG/300ML

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Deny if not prescribed by an infectious disease (ID) specialist or prescribed with ID consultation (telephone consultation is acceptable) including name of the ID specialist and date of the consultation within the last 60 days
Coverage Duration	1 month
Other Criteria	Documentation of a current bacterial infection and an inadequate response or inability to tolerate at least TWO drugs to which the organism is susceptible OR the requested agent is the only antibiotic to which the organism is susceptible. RE-AUTHORIZATION CRITERIA: Documentation that an infectious disease consult determines that a longer duration of therapy is required.

NON-ORAL CHEMO AGENTS

Products Affected

- ABRAXANE
- ADRIAMYCIN INTRAVENOUS SOLUTION
- ADRUCIL INTRAVENOUS SOLUTION 500 MG/10ML
- ALIMTA
- ALIQOPA
- ALKERAN INTRAVENOUS
- ARRANON
- AVASTIN
- *azacitidine*
- BAVENCIO
- BELEODAQ
- BICNU
- *bleomycin sulfate injection solution reconstituted 30 unit*
- *bortezomib*
- *busulfan*
- BUSULFEX
- CAMPTOSAR INTRAVENOUS SOLUTION 100 MG/5ML
- *carboplatin intravenous solution 150 mg/15ml*
- *cisplatin intravenous solution 50 mg/50ml*
- *cladribine intravenous solution 10 mg/10ml*
- *clofarabine*
- CLOLAR
- COSMEGEN
- CYRAMZA
- *cytarabine (pf) injection solution 100 mg/ml*
- *cytarabine injection solution*
- *dacarbazine intravenous solution reconstituted 200 mg*
- DACOGEN
- *dactinomycin*
- DARZALEX INTRAVENOUS SOLUTION 100 MG/5ML
- *decitabine*
- *dexrazoxane intravenous solution reconstituted 250 mg*
- *docetaxel intravenous concentrate 80 mg/4ml*
- *docetaxel intravenous solution 160 mg/16ml*
- DOXIL
- *doxorubicin hcl intravenous solution*
- *doxorubicin hcl liposomal*
- ELLENCE INTRAVENOUS SOLUTION 200 MG/100ML
- EMPLICITI
- *epirubicin hcl intravenous solution 200 mg/100ml*
- ERBITUX INTRAVENOUS SOLUTION 100 MG/50ML
- ERWINAZE INJECTION
- ETOPOPHOS
- *etoposide intravenous solution 100 mg/5ml*
- *fludarabine phosphate intravenous solution reconstituted*
- *fluorouracil intravenous solution 5 gm/100ml*
- FOLOTYN INTRAVENOUS SOLUTION 40 MG/2ML
- *gemcitabine hcl intravenous solution reconstituted 1 gm*
- GEMZAR INTRAVENOUS SOLUTION RECONSTITUTED 1 GM
- HALAVEN
- HERCEPTIN
- HYCAMTIN INTRAVENOUS
- IDAMYCIN PFS INTRAVENOUS SOLUTION 20 MG/20ML
- *idarubicin hcl intravenous solution 10 mg/10ml*
- IFEX INTRAVENOUS SOLUTION RECONSTITUTED 1 GM
- *ifosfamide intravenous solution reconstituted 1 gm*
- IMFINZI
- *irinotecan hcl intravenous solution 100 mg/5ml*
- ISTODAX (OVERFILL)
- JEVTANA
- KADCYLA
- KEYTRUDA INTRAVENOUS SOLUTION
- KYPROLIS INTRAVENOUS SOLUTION RECONSTITUTED 30 MG, 60 MG
- LARTRUVO
- *melphalan hcl*
- *mitomycin intravenous*
- *mitoxantrone hcl intravenous concentrate 25 mg/12.5ml*
- MUSTARGEN

- MYLOTARG INTRAVENOUS SOLUTION RECONSTITUTED 4.5 MG
- NIPENT
- OPDIVO INTRAVENOUS SOLUTION 100 MG/10ML, 40 MG/4ML
- *oxaliplatin intravenous solution 100 mg/20ml*
- *oxaliplatin intravenous solution reconstituted 100 mg*
- *paclitaxel intravenous concentrate 100 mg/16.7ml*
- PERJETA
- RITUXAN INTRAVENOUS SOLUTION
- SYNRIBO
- TAXOTERE INTRAVENOUS CONCENTRATE 80 MG/4ML
- TECENTRIQ
- *thiotepa injection*
- TOPOSAR INTRAVENOUS SOLUTION 1 GM/50ML
- *topotecan hcl intravenous solution reconstituted*
- TORISEL
- TREANDA INTRAVENOUS SOLUTION RECONSTITUTED
- TRISENOX INTRAVENOUS SOLUTION 12 MG/6ML
- VECTIBIX INTRAVENOUS SOLUTION 100 MG/5ML
- VELCADE INJECTION
- VIDAZA
- *vinblastine sulfate intravenous solution*
- VINCASAR PFS
- *vincristine sulfate intravenous*
- *vinorelbine tartrate intravenous solution 50 mg/5ml*
- VYXEOS INTRAVENOUS SUSPENSION RECONSTITUTED 44-100 MG
- YERVOY INTRAVENOUS SOLUTION 50 MG/10ML
- YONDELIS
- ZALTRAP INTRAVENOUS SOLUTION 100 MG/4ML
- ZANOSAR
- ZINECARD INTRAVENOUS SOLUTION RECONSTITUTED 250 MG

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Indefinite
Other Criteria	Subject to Part B vs Part D review and if part D is medically necessary when ANY of the following inclusion criteria is met: (1) Drug is FDA approved for indication and regimen requested, (2) The indication and regimen is classified as Category 1 or 2A by National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium, (3) narrative text in The American Hospital Formulary Service-Drug Information (AHFS-DI) or Clinical Pharmacology Compendium is supportive for the specific condition(s) requested, (4) The Micromedex Compendium and the strength of recommendation is listed as Class I, Class IIa, or Class IIb for the specific condition(s) requested, (5) Indication is listed in Lexi-Drugs as off label with evidence level A, (6) Documentation of continuous therapy with the medication requested

NOXAFIL

Products Affected

- NOXAFIL ORAL

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	Deny if less than 13 years
Prescriber Restrictions	Prescribed by or in consultation with an infectious disease specialist
Coverage Duration	Remainder of contract year
Other Criteria	Documentation of either of the following (1) for use in prophylaxis of invasive Aspergillus and Candida infections due to being severely immunocompromised after inadequate response or inability to tolerate voriconazole (Vfend) OR (2) for a diagnosis of oropharyngeal candidiasis after inadequate response or inability to tolerate both itraconazole and fluconazole

NUCALA

Products Affected

- NUCALA

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	Deny if patient is less than 12 years of age
Prescriber Restrictions	Prescribed by or in consultation with pulmonologist or allergy/immunology specialist
Coverage Duration	Initial authorization: 3 months Re-authorization: Remainder of contract year
Other Criteria	Subject to Part B vs Part D review and if part D is medically necessary when there is documentation of all of the following: 1) Diagnosis of severe asthma with eosinophillic phenotype as defined by one of the following: a) blood eosiniophil levels are at least 150 cells/microliter at initiation of therapy, or b) blood eosinophil levels at least 300 cells/microliter within the past 12 months, and 3) Patient is currently treated with high-dose inhaled corticosteroids (ICS) (e.g., greater than or equal to 880mcg fluticasone propionate equivalent/day) AND an additional controller medication (e.g., long-acting beta agonist such as salmeterol or formoterol, leukotriene inhibitor such as montelukast, theophylline), unless the individual is intolerant of or has a contraindication to two of the additional controller agents Reauthorization criteria: Patient is currently treated with high-dose inhaled corticosteroids (ICS) (e.g., greater than or equal to 880mcg fluticasone propionate equivalent/day) AND an additional controller medication (e.g., long-acting beta agonist such as salmeterol or formoterol, leukotriene inhibitor such as montelukast, theophylline), unless the individual is intolerant of or has a contraindication to two of the additional controller agents

NUEDEXTA

Products Affected

- NUEDEXTA

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	Deny if less than 18 years
Prescriber Restrictions	
Coverage Duration	Indefinite
Other Criteria	Documentation of Pseudobulbar affect

NULOJIX

Products Affected

- NULOJIX

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	Transplant recipients who are Epstein-Barr virus seronegative or with unknown Epstein-Barr virus serostatus
Required Medical Information	
Age Restrictions	Deny if less than 18 years
Prescriber Restrictions	Prescribed by a nephrologist or transplant specialist
Coverage Duration	Indefinite
Other Criteria	Subject to Part B vs Part D review and if part D is medically necessary when the beneficiary did not receive a transplant from a Medicare-approved facility or were not entitled or qualified for Medicare Part A at the time of the transplant AND when ONE of the following: (1) documentation of continuous therapy with belatacept (Nulojix) OR (2) for prophylaxis of organ rejection in adults receiving a kidney transplant, in combination with basiliximab induction, mycophenolate mofetil, and corticosteroids

NUPLAZID

Products Affected

- NUPLAZID ORAL TABLET 17 MG

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Indefinite
Other Criteria	Documentation of inadequate response or inability to tolerate ONE of the following (1) quetiapine or (2) clozapine.

OCALIVA

Products Affected

- OCALIVA

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Prescribed by or in consultation with hepatologist or gastroenterologist
Coverage Duration	Initial authorization is 6 months and Reauthorization=Indefinite
Other Criteria	Approved when One of the following is met: (1) Used in combination with ursodeoxycholic acid and patient had suboptimal response to at least 12 consecutive months of treatment with ursodeoxycholic acid (e.g., Urso, Urso Forte, ursodiol), OR (2) inability to tolerate ursodeoxycholic acid . Reauthorization is approved with documentation of positive clinical response to Ocaliva therapy

OLUMIANT

Products Affected

- OLUMIANT

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	Concurrent therapy with any other biologic disease modifying anti-rheumatic drug (DMARD), e.g. tumor necrosis factor antagonists
Required Medical Information	Documentation for evaluation of active or latent Tuberculosis (TB)
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	Recommended by a rheumatologist
Coverage Duration	Indefinite
Other Criteria	Documentation of ONE of the following: (1) inadequate response or inability to tolerate adalimumab (Humira) AND etanercept (Enbrel) or (2) documentation demonstrating that a trial may be inappropriate

ORACEA

Products Affected

- ORACEA

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Remainder of contract year
Other Criteria	Documentation of diagnosis of inflammatory lesions of rosacea AND inadequate response or inability to tolerate generic doxycycline

ORAL ANTIBIOTICS

Products Affected

- *linezolid oral*
- SIVEXTRO
- ZYVOX ORAL

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Deny if not prescribed by an infectious disease (ID) specialist or prescribed with ID consultation (telephone consultation is acceptable) including name of the ID specialist and date of the consultation within the last 60 days
Coverage Duration	1 month
Other Criteria	Documentation of a current bacterial infection and an inadequate response or inability to tolerate TWO antibiotics to which the organism is susceptible OR the requested medication is the only antibiotic to which the organism is susceptible. RE-AUTHORIZATION CRITERIA: Documentation that an infectious disease consult determines that a longer duration of therapy is required.

ORAL CHEMO AGENTS

Products Affected

- AFINITOR
- AFINITOR DISPERZ
- ALECENSA
- ALUNBRIG
- *bexarotene*
- BOSULIF
- CABOMETYX
- CALQUENCE
- CAPRELSA
- COMETRIQ (100 MG DAILY DOSE)
- COMETRIQ (140 MG DAILY DOSE)
- COMETRIQ (60 MG DAILY DOSE)
- COTELLIC
- ERIVEDGE
- ERLEADA
- FARYDAK
- GILOTRIF
- GLEEVEC
- GLEOSTINE ORAL CAPSULE 10 MG, 100 MG, 40 MG
- IBRANCE
- ICLUSIG
- IDHIFA
- *imatinib mesylate*
- IMBRUVICA
- INLYTA
- IRESSA
- JAKAFI
- KISQALI 200 DOSE
- KISQALI 400 DOSE
- KISQALI 600 DOSE
- KISQALI FEMARA 200 DOSE
- KISQALI FEMARA 400 DOSE
- KISQALI FEMARA 600 DOSE
- LENVIMA 10 MG DAILY DOSE
- LENVIMA 14 MG DAILY DOSE
- LENVIMA 18 MG DAILY DOSE
- LENVIMA 20 MG DAILY DOSE
- LENVIMA 24 MG DAILY DOSE
- LENVIMA 8 MG DAILY DOSE
- LONSURF
- LYNPARZA
- MEKINIST
- NERLYNX
- NEXAVAR
- NINLARO
- ODOMZO
- POMALYST
- REVLIMID
- RUBRACA
- RYDAPT
- SPRYCEL
- STIVARGA
- SUTENT
- TAFINLAR
- TAGRISSO
- TARCEVA
- TARGRETIN ORAL
- TASIGNA
- THALOMID
- TYKERB
- VENCLEXTA
- VENCLEXTA STARTING PACK
- VERZENIO
- VOTRIENT
- XALKORI
- XTANDI
- YONSA
- ZEJULA
- ZELBORAF
- ZOLINZA
- ZYDELIG
- ZYKADIA
- ZYTIGA

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Indefinite
Other Criteria	Approved when ANY of the following inclusion criteria is met: (1) Drug is FDA approved for indication and regimen requested, (2) The indication and regimen is classified as Category 1 or 2A by National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium, (3) narrative text in The American Hospital Formulary Service-Drug Information (AHFS-DI) or Clinical Pharmacology Compendium is supportive for the specific condition(s) requested, (4) The Micromedex Compendium and the strength of recommendation is listed as Class I, Class IIa, or Class IIb for the specific condition(s) requested, (5) Indication is listed in Lexi-Drugs as off label with evidence level A (6) Documentation of continuous therapy with the medication requested

ORAL PAH AGENTS

Products Affected

- LETAIRIS
- OPSUMIT
- ORENITRAM
- TRACLEER

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Deny if not prescribed by Cardiologist or Pulmonologist
Coverage Duration	6 month for initial authorization and 12 months for renewal authorizations
Other Criteria	Approved when all of the following inclusion criteria are met: (1) Documentation of a diagnosis of pulmonary arterial hypertension (PAH) WHO Group I with New York Heart Association (NYHA) Functional Class II to IV, (2) Diagnosis confirmed by catheterization (right-heart or Swan-Ganz) or echocardiography AND (3) Documentation of mean pulmonary artery pressure greater than or equal to 25 mm Hg at rest or greater than 30 mm Hg with exertion. RE-AUTHORIZATION CRITERIA: Documentation of stabilization or improvement as evaluated by a cardiologist or pulmonologist.

ORALAIR

Products Affected

- ORALAIR

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	Deny if patient has severe, unstable or uncontrolled asthma OR history of eosinophilic esophagitis
Required Medical Information	Patient has a positive skin test or in vitro test for any of the five grass species including sweet vernal, orchard, perennial rye, timothy or Kentucky blue grass mixed pollens
Age Restrictions	Deny if less than 10 years OR over 65 years of age
Prescriber Restrictions	Deny if not prescribed by allergist or immunologist
Coverage Duration	Remainder of contract year
Other Criteria	Patient has had an inadequate response or inability to tolerate intranasal corticosteroid and an antihistamine. Reauthorization criteria: Patient has experienced improvement in the symptoms of their allergic rhinitis OR a decrease in the number of medications needed to control allergy symptoms

ORENCIA IV

Products Affected

- ORENCIA INTRAVENOUS

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	Concurrent therapy with biological DMARDs or other tumor necrosis factor antagonists
Required Medical Information	Documentation for evaluation of active or latent Tuberculosis (TB). For new starts only: at least 2 weeks passed since administration of Herpes Zoster vaccine prior to start of therapy.
Age Restrictions	Deny if less than 6 years
Prescriber Restrictions	Medication is being recommended by a rheumatologist
Coverage Duration	Indefinite
Other Criteria	Subject to Part B vs Part D review and if part D is medically necessary when given in the home setting or long term care facility and is considered medically necessary when there is documentation of adult rheumatoid arthritis , psoriatic arthritis, or juvenile idiopathic arthritis with an inadequate response to at least ONE disease-modifying antirheumatic drug (DMARDs) such as methotrexate

ORENCIA SQ

Products Affected

- ORENCIA CLICKJECT
- ORENCIA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	Concurrent therapy with biological DMARDs or other tumor necrosis factor antagonists
Required Medical Information	Documentation for evaluation of active or latent Tuberculosis (TB). For new starts only: at least 2 weeks passed since administration of Herpes Zoster vaccine prior to start of therapy.
Age Restrictions	Deny if less than 2 years
Prescriber Restrictions	Medication is being recommended by a rheumatologist
Coverage Duration	Indefinite
Other Criteria	Documentation of either (1) inadequate response or inability to tolerate adalimumab (Humira) and etanercept (Enbrel) OR documentation demonstrating that a trial may be inappropriate

ORKAMBI

Products Affected

- ORKAMBI ORAL TABLET

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	Diagnosis of CF other than those homozygous for the F508del mutation
Required Medical Information	If the patient's genotype is unknown, an FDA-cleared CF mutation test should be used to detect the presence of the F508del mutation on both alleles of the CFTR gene
Age Restrictions	Deny if age is less than 6
Prescriber Restrictions	
Coverage Duration	Indefinite
Other Criteria	Documentation of ALL of the following: (1) Diagnosis of Cystic Fibrosis, (2) Patient is homozygous for the F508del mutation in the CFTR gene

OTEZLA

Products Affected

- OTEZLA ORAL TABLET
- OTEZLA ORAL TABLET THERAPY PACK

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	Documentation for evaluation of active or latent Tuberculosis (TB)
Age Restrictions	Deny if less than 18 years
Prescriber Restrictions	Recommended by Rheumatologist or Dermatologist
Coverage Duration	Indefinite
Other Criteria	Documentation of BOTH of the following: (1) diagnosis of psoriatic arthritis or plaque psoriasis AND (2) inadequate response or inability to tolerate both adalimumab (Humira) AND etanercept (Enbrel)

PALYNZIQ

Products Affected

- PALYNZIQ

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	Initial: 6 months, Continuation: Indefinite
Other Criteria	CONTINUATION CRITERIA: Documentation of a positive clinical response to Palynziq therapy

PART D VS EXCLUDED

Products Affected

- AURYXIA
- IMVEXXY MAINTENANCE PACK VAGINAL INSERT 10 MCG
- INTRAROSA
- OSPHENA

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Indefinite
Other Criteria	

PDE INHIBITOR AGENTS FOR PAH

Products Affected

- ADCIRCA
- REVATIO

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Deny if not prescribed by Cardiologist or Pulmonologist
Coverage Duration	6 months for initial approvals and 12 months for renewals
Other Criteria	Documentation of ALL of the following: (1) Diagnosis of pulmonary arterial hypertension (PAH) WHO Group I with New York Heart Association (NYHA) Functional Class II to IV, (2) Diagnosis confirmed by catheterization (right-heart or Swan-Ganz) or echocardiography, (3) Mean pulmonary artery pressure greater than or equal to 25 mm Hg at rest or greater than 30 mm Hg with exertion. (4) inadequate response or inability to tolerate sildenafil RE-AUTHORIZATION CRITERIA: Documentation of stabilization or improvement as evaluated by a cardiologist or pulmonologist.

PICATO

Products Affected

- PICATO

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	One Month
Other Criteria	Documentation of BOTH of the following: (1) diagnosis of actinic keratosis AND (2) inadequate response or inability to tolerate one previous therapy (i.e. diclofenac gel 3%, imiquimod, flurouracil).

PRALUENT

Products Affected

- PRALUENT SUBCUTANEOUS SOLUTION PEN-INJECTOR

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 months
Other Criteria	Diagnosis of either hyperlipidemia or atherosclerotic cardiovascular disease (ASCVD) as diagnosed by either stress test, angiography, atherosclerotic event (e.g. MI, angina, stroke, claudication, carotid stenosis) or arterial intervention for atherosclerotic disease (e.g. coronary, peripheral, carotid) AND ONE of the following: (1) LDL-C 70 mg/dL or greater after a minimum 8-week trial of at least moderate-intensity statin therapy OR (2) Inability to tolerate statin therapy as documented by one of the following: (a) member had rhabdomyolysis or symptoms with creatine kinase (CK) exceeding 10 times the upper limit of normal (ULN) or (b) either of the following with TWO statins: myalgia (no CK elevation) or myositis (CK less than 10 times ULN or (c) hepatotoxicity from statin use (increased AST/ALT exceeding 3 times ULN) or (d) liver disease documented by Child Pugh A or worse OR AST/ALT exceeding 3 times ULN for at least 6 weeks Re-authorization criteria: approved for 12 months if there is documentation of sustained reduction in LDL-C from start of therapy

PROCYSBI

Products Affected

- PROCYSBI

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	Hypersensitivity to penicillamine
Required Medical Information	
Age Restrictions	Deny if less than 2 years
Prescriber Restrictions	
Coverage Duration	3 months for initial authorization and 6 months for renewal authorization
Other Criteria	Diagnosis of nephrotic cystinosis AND documentation of inadequate response or titration from cysteamine bitartrate immediate-release capsules (Cystagon) AND documentation of baseline WBC and alkaline phosphatase levels. REAUTHORIZATION CRITERIA: Documentation of monitoring ALL of the following at least ONCE since previous authorization (1) ONE of the following: (a) WBC cysteine level or (b) plasma cysteamine level (2) WBC count AND (3) alkaline phosphatase level

PROLIA

Products Affected

- PROLIA

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Indefinite
Other Criteria	Subject to Part B vs Part D review and if part D is medically necessary for the treatment OSTEOPOROSIS when BOTH of the following are met: (1) ONE of the following: (a) T-score less than or equal to -2.5 (b) history of osteoporotic fracture (e.g., vertebral, hip, non-vertebral) or (c) multiple risk factors for fracture, AND (2) ONE of the following: (a) inadequate response or inability to tolerate at least one other osteoporosis medicine (e.g., oral bisphosphonates, calcitonin, estrogens, selective estrogen receptor modulator (SERMs)) or (b) severely deteriorated condition indicating that the osteoporosis is so significant that a trial of oral bisphosphonates is not medically warranted. For the treatment of OSTEOPENIA: (T-score less than -1.0, but greater than -2.5), with ONE of the following: (a) receiving adjuvant aromatase inhibitor therapy for breast cancer or (b) receiving androgen deprivation therapy for non-metastatic prostate cancer.

PROVIGIL/NUVIGIL

Products Affected

- *armodafinil*
- NUVIGIL
- PROVIGIL

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	For NARCOLEPSY or SHIFT WORK SLEEP DISORDER (SWSD): Recommended by a neurologist or sleep specialist
Coverage Duration	Indefinite
Other Criteria	Documentation of inadequate response or inability to tolerate generic modafinil AND one of the following (1) FOR NARCOLEPSY: Documentation of a diagnosis of Narcolepsy. (2) FOR OBSTRUCTIVE SLEEP APNEA/HYPOPNEA SYNDROME (OSAHS): Documentation that the medication is being used as an adjunct treatment for the underlying obstruction. (3) FOR SHIFT WORK SLEEP DISORDER (SWSD): Documentation that the member has no medical or mental disorder accounting for the symptoms AND the symptoms do not meet criteria for any other sleep disorder producing insomnia or excessive sleepiness (e.g. time-zone change [jet lag] syndrome)

PULMONARY FIBROSIS AGENTS

Products Affected

- ESBRIET
- OFEV

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Deny if not prescribed by an appropriate specialist such as pulmonologist or lung transplant
Coverage Duration	12 months initial and reauthorization
Other Criteria	Diagnosis of idiopathic pulmonary fibrosis confirmed by high resolution CT scan or biopsy REAUTHORIZATION CRITERIA: BOTH of the following (1) stabilization from baseline or a less than 10% decline in forced vital capacity AND (2) no elevations in AST or ALT greater than 5 times upper limit of normal or greater than 3 times upper limit of normal with signs or symptoms of severe liver damage

QUALAQUIN

Products Affected

- QUALAQUIN
- *quinine sulfate oral*

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Remainder of contract year
Other Criteria	Diagnosis of uncomplicated plasmodium falciparum malaria

RADICAVA

Products Affected

- RADICAVA

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Deny if not prescribed by a neurologist experienced in treating ALS
Coverage Duration	Initial authorization: 6 months, Reauthorization: 6 months
Other Criteria	ALL of the following (1) Diagnosis of definite or probable amyotrophic lateral sclerosis (ALS) per the revised El Escorial World Federation of Neurology criteria (2) Time from symptom onset is 2 years or less (3) Normal respiratory function as defined as forced vital capacity (FVC) of greater than or equal to 80% (4) Scores of 2 points or greater on each individual item of the ALS Functional Rating Scale-revised (ALSFRS-R) Reauthorization criteria: member is not permanently ventilator dependent

RAVICTI

Products Affected

- RAVICTI

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	Acute hyperammonemia. N-acetylglutamate synthase (NAGS) deficiency
Required Medical Information	
Age Restrictions	Deny if less than age 2 months
Prescriber Restrictions	
Coverage Duration	Remainder of contract year
Other Criteria	Documentation of BOTH of the following: (1) diagnosis of urea cycle disorder involving deficiencies of carbamoyl phosphate synthetase (CPS), ornithine transcarbamoylase (OTC), or argininosuccinic acid synthetase (AAS) confirmed via enzymatic, biochemical, or genetic testing, (2) inadequate response or inability to tolerate sodium phenylbutyrate

REMODULIN

Products Affected

- REMODULIN

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Deny if not prescribed by pulmonologist or cardiologist
Coverage Duration	Indefinite
Other Criteria	Subject to Part B vs Part D review and if part D is medically necessary when BOTH of the following are met (1) diagnosis of pulmonary arterial hypertension (World Health Organization group 1) (2) mean pulmonary artery pressures greater than or equal to 25 mm Hg at rest by right heart catheterization or echocardiography and (3) NYHA functional class II through IV symptoms

REPATHA

Products Affected

- REPATHA
- REPATHA PUSHTRONEX SYSTEM
- REPATHA SURECLICK

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 months
Other Criteria	Diagnosis of either hyperlipidemia, homozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease (ASCVD) as diagnosed by either stress test, angiography, atherosclerotic event (e.g. MI, angina, stroke, claudication, carotid stenosis) or arterial intervention for atherosclerotic disease (e.g. coronary, peripheral, carotid) AND ONE of the following: (1) LDL-C 70 mg/dL or greater after a minimum 8-week trial of at least moderate-intensity statin therapy OR (2) Inability to tolerate statin therapy as documented by one of the following: (a) member had rhabdomyolysis or symptoms with creatine kinase (CK) exceeding 10 times the upper limit of normal (ULN) on any statin or (b) either of the following with TWO statins: myalgia (no CK elevation) or myositis (CK less than 10 times ULN or (c) hepatotoxicity from statin use (increased AST/ALT exceeding 3 times ULN) or (d) liver disease documented by Child Pugh A or worse OR AST/ALT exceeding 3 times ULN for at least 6 weeks. Re-authorization criteria: approved for 12 months if there is documentation of sustained reduction in LDL-C from baseline

RESPIRATORY ENZYMES

Products Affected

- ARALAST NP INTRAVENOUS SOLUTION RECONSTITUTED 1000 MG
- GLASSIA
- PROLASTIN-C INTRAVENOUS SOLUTION RECONSTITUTED 1000 MG
- ZEMAIRA

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	IgA deficiency with known anti-IgA antibody
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Indefinite
Other Criteria	Subject to Part B vs Part D review and if part D is medically necessary when BOTH of the following are met: (1) low serum concentration of alpha-1 antitrypsin defined as less than 35 percent of normal (less than 80 mg/dL or less than 11 uM/L or less than 0.8 g/L) (2) the individual has progressive panacinar emphysema with a documented rate of decline in forced expiratory volume in 1 second (FEV 1)

SAMSCA

Products Affected

- SAMSCA

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	(1) patients who are unable to sense or appropriately respond to thirst, hypovolemic hyponatremia (2) concomitant use of strong CYP3A inhibitors
Required Medical Information	
Age Restrictions	Deny if less than 18 years
Prescriber Restrictions	Deny if not prescribed by cardiologist, endocrinologist or nephrologist
Coverage Duration	Indefinite
Other Criteria	Documentation of a diagnosis of clinically significant hypervolemic or euvolemic hyponatremia and BOTH of the following (1) ONE of the following (a) serum sodium less than 125meq/L or (b) serum sodium 125-135 meq/L with symptoms (2) inadequate response or inability to tolerate therapies to control hyponatremia (ie fluid restriction, diuretics, demeclocycline)

SAVELLA

Products Affected

- SAVELLA
- SAVELLA TITRATION PACK

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	Deny if less than 18 years
Prescriber Restrictions	
Coverage Duration	Indefinite
Other Criteria	Diagnosis of fibromyalgia and inadequate response or inability to tolerate generic duloxetine

SEROSTIM

Products Affected

- SEROSTIM SUBCUTANEOUS SOLUTION RECONSTITUTED 4 MG, 5 MG, 6 MG

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Deny if not prescribed by HIV specialist
Coverage Duration	48weeks
Other Criteria	Wasting or cachexia associated with HIV

SIGNIFOR

Products Affected

- SIGNIFOR

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	Deny if less than 18 years
Prescriber Restrictions	
Coverage Duration	Remainder of contract year
Other Criteria	Documentation of BOTH of the following: (1) diagnosis of (pituitary) Cushing's disease AND (2) pituitary surgery is not an option or has not been curative

SIGNIFOR LAR

Products Affected

- SIGNIFOR LAR INTRAMUSCULAR SUSPENSION RECONSTITUTED ER 20 MG, 40 MG, 60 MG

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	Deny if less than 18 years
Prescriber Restrictions	
Coverage Duration	Remainder of contract year
Other Criteria	Subject to Part B vs Part D review and if part D is medically necessary there is documentation of a diagnosis of acromegaly in patients with an inadequare repsonse to surgery or who are not candidates for surgery

SILDENAFIL

Products Affected

- *sildenafil citrate intravenous*
- *sildenafil citrate oral tablet 20 mg*

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	Documentation of concomitant nitrate use
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Deny if not prescribed by Cardiologist or Pulmonologist
Coverage Duration	Indefinite
Other Criteria	Documentation of ONE of the following: (1) Diagnosis of pulmonary arterial hypertension (PAH) WHO Group I with New York Heart Association (NYHA) Functional Class II to IV and BOTH of the following (a) Diagnosis confirmed by catheterization (right-heart or Swan-Ganz) or echocardiography, (b) Mean pulmonary artery pressure greater than or equal 25 mm Hg at rest or greater than 30 mm Hg with exertion. (2) diagnosis of secondary Raynaud's phenomenon and inadequate response or inability to tolerate a calcium channel blocker

SILENOR

Products Affected

- SILENOR

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Remainder of contract year
Other Criteria	Documentation of insomnia with inadequate response or inability to tolerate ramelteon (Rozerem)

SILIQ

Products Affected

- SILIQ

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	Concurrent therapy with biological DMARDs or other tumor necrosis factor antagonists
Required Medical Information	Documentation for evaluation of active or latent Tuberculosis (TB). For new starts only: at least 2 weeks passed since administration of live vaccines prior to the start of therapy.
Age Restrictions	Deny if less than 18 years
Prescriber Restrictions	Deny if not prescribed by a dermatologist
Coverage Duration	Initial: 16 weeks Reauthorization: 1 year
Other Criteria	Documentation of ALL of the following: 1) plaque psoriasis and 2) inadequate response or inability to tolerate both adalimumab (Humira) AND etanercept (Enbrel) or documentation demonstrating that a trial may be inappropriate 3) member has been evaluated for depression and suicidal ideations using the PHQ-9 Reauthorization criteria BOTH of the following: 1) member has positive response to therapy 2) member has been evaluated for depression and suicidal ideations using the PHQ-9

SIMPONI

Products Affected

- SIMPONI SUBCUTANEOUS SOLUTION AUTO-INJECTOR
- SIMPONI SUBCUTANEOUS SOLUTION PREFILLED SYRINGE

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	Concurrent therapy with any other biologic disease modifying anti-rheumatic drug (DMARD), e.g. tumor necrosis factor antagonists
Required Medical Information	Documentation for evaluation of active or latent Tuberculosis (TB). For new starts only: at least 2 weeks passed since administration of Herpes Zoster vaccine prior to start of therapy.
Age Restrictions	Deny if less than 18 years
Prescriber Restrictions	Deny if not prescribed by Rheumatologist, gastroenterologist, or dermatologist
Coverage Duration	Indefinite
Other Criteria	Ankylosing Spondylitis or Psoriatic Arthritis: inadequate response or inability to tolerate to both adalimumab (Humira) AND etanercept (Enbrel) or documentation demonstrating that a trial may be inappropriate. Rheumatoid arthritis: BOTH of the following (1) inadequate response or inability to tolerate to both adalimumab (Humira) AND etanercept (Enbrel) or documentation demonstrating that a trial may be inappropriate AND (2) concurrent therapy with methotrexate Ulcerative Colitis: inadequate response or inability to tolerate adalimumab (Humira) or documentation demonstrating that a trial may be inappropriate

SIMPONI ARIA

Products Affected

- SIMPONI ARIA

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	Concurrent therapy with any other biologic disease modifying anti-rheumatic drug (DMARD), e.g. tumor necrosis factor antagonists
Required Medical Information	Documentation for evaluation of active or latent Tuberculosis (TB). For new starts only: at least 2 weeks passed since administration of Herpes Zoster vaccine prior to start of therapy.
Age Restrictions	Deny if less than 18 years
Prescriber Restrictions	Deny if not prescribed by Rheumatologist.
Coverage Duration	Indefinite
Other Criteria	Subject to Part B vs Part D review and if part D is medically necessary when BOTH of the following are met (1) inadequate response to methotrexate AND and (2) concurrent use with methotrexate

SIRTURO

Products Affected

- SIRTURO

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	Sirturo (bedaquiline) will be administered by directly observed therapy (DOT).
Age Restrictions	Deny if less than 18 years
Prescriber Restrictions	Recommended by infectious disease specialist or pulmonologist
Coverage Duration	24 weeks
Other Criteria	Documentation of ONE of the following: (1) medication will be used in combination with at least 3 other drugs to which the patient's MDR-TB isolate has been shown to be susceptible in vitro OR (2) If in vitro testing results are unavailable, treatment will be initiated in combination with at least 4 other drugs to which the patient's MDR-TB isolate is likely to be susceptible.

STELARA

Products Affected

- STELARA INTRAVENOUS PREFILLED SYRINGE
- STELARA SUBCUTANEOUS SOLUTION 45 MG/0.5ML
- STELARA SUBCUTANEOUS SOLUTION

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	Documentation for evaluation of active or latent Tuberculosis (TB)
Age Restrictions	Deny if less than 18 years
Prescriber Restrictions	Deny if not prescribed by Dermatologist, Gastroenterologist, or Rheumatologist
Coverage Duration	Indefinite
Other Criteria	Subject to Part B vs Part D review and if part D is medically necessary when there is an inadequate response or inability to tolerate to both adalimumab (Humira) AND etanercept (Enbrel) or documentation demonstrating that a trial may be inappropriate

STRENSIQ

Products Affected

- STRENSIQ SUBCUTANEOUS SOLUTION
  40 MG/ML, 80 MG/0.8ML

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	For patients requesting 80mg/0.8ml vial: patient's weight is greater than or equal to 40kg
Age Restrictions	
Prescriber Restrictions	Prescribed by or in consultation with a specialist experienced in the treatment of inborn errors of metabolism or endocrinologist
Coverage Duration	Indefinite
Other Criteria	

SYLATRON

Products Affected

- SYLATRON SUBCUTANEOUS KIT 200 MCG, 300 MCG, 600 MCG

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	autoimmune hepatitis, hepatic decompensation
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Deny if not prescribed by dermatologist or oncologist
Coverage Duration	Indefinite
Other Criteria	Subject to Part B vs Part D review and if part D is medically necessary when ONE of the following inclusion criteria is met:(1) use for adjuvant treatment of melanoma with microscopic or gross nodal involvement within 84 days of definitive surgical resection including complete lymphadenectomy OR (2) documentation of continuous therapy with Peginterferon alfa-2b (Sylatron)

SYLVANT

Products Affected

- SYLVANT

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Remainder of contract year
Other Criteria	Subject to Part B vs Part D review and if part D is medically necessary when there is a diagnosis of multicentric Castleman disease (MCD) and BOTH HIV negative and human herpesvirus-8 (HHV-8) negative

SYMDEKO

Products Affected

- SYMDEKO

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	If the patient's genotype is unknown, an FDA-cleared test must be used to detect the presence of CFTR mutation followed by verification with bi-directional sequencing when recommended by the mutation test
Age Restrictions	Deny if age less than 12 years
Prescriber Restrictions	Prescribed by pulmonologist
Coverage Duration	Indefinite
Other Criteria	Documentation of ALL of the following (1) Diagnosis of Cystic Fibrosis, (2) One of the following: a) Member is homozygous for the F508del mutation, or b) Member has at least one tezacaftor/ivacaftor responsive mutation in the CFTR gene.

SYMLIN

Products Affected

- SYMLINPEN 120 SUBCUTANEOUS SOLUTION PEN-INJECTOR
- SYMLINPEN 60 SUBCUTANEOUS SOLUTION PEN-INJECTOR

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Indefinite
Other Criteria	Documentation of diagnosis of diabetes (Type 1 or Type 2) and both of the following: (1) inadequate response to optimal insulin monotherapy and (2) concurrent use of mealtime insulin

SYNAGIS

Products Affected

- SYNAGIS

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Max 5 doses

PA Criteria	Criteria Details
Other Criteria	Subject to Part B vs Part D review and if part D is medically necessary for the prophylaxis of respiratory syncytial virus (RSV) when ONE of the following is met: (1) Infants born before 29 wks, 0 days gestation and are less than 12 mos at start of RSV season (2) Infants and children with chronic lung disease (CLD) of prematurity defined as gestational age (GA) less than 32 wks, 0 days and a requirement for greater than 21% oxygen for at least 28 days after birth and one of the following: (a) during the first year of life (b) during the second year of life who require medical therapy for CLD within the six mos before start of the RSV season. (Medical therapy includes any of the following: requirement for supplemental oxygen, use of bronchodilators, diuretic therapy or corticosteroid) (3) Infants with congenital heart disease (CHD) who are 12 mos of age or younger at the start of the RSV season and meet the following criteria: (a) hemodynamically significant acyanotic CHD and receiving medication for congestive heart failure and will require a cardiac surgery procedure (b) hemodynamically significant cyanotic CHD after consultation with a pediatric cardiologist (c) diagnosis of moderate-to-severe pulmonary hypertension (4) Infants 12 mos of age or younger at start of RSV season with either of the following: (a) congenital abnormalities of the airway (b) neuromuscular disease that compromises mobilization of respiratory secretions (5) Infants and children younger than 24 mos of age who are profoundly immunocompromised (e.g., due to transplantation or chemotherapy) during the RSV season (6) Infants and children younger than 24 months with cystic fibrosis (CF) when at least one of the following: (a) Nutritional compromise, (b) Manifestations of severe lung disease (previous hospitalization for pulmonary exacerbation in the first year of life or abnormalities on chest radiography or chest computed tomography that persists when stable). CRITERIA FOR ONE ADDITIONAL POST OP DOSE: Documentation of ALL of the following: (1) age less than 24 mos (2) currently receiving palivizumab (3) medically stable (4) meet the above criteria for immune prophylaxis AND (5) have undergone ONE of the following procedures during the current RSV season: (1) Surgical procedures that use cardiopulmonary bypass (2) Cardiac transplantation. MAX OF 5 MONTHLY DOSES.

TALTZ

Products Affected

- TALTZ

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	Concurrent therapy with biological DMARDs or other tumor necrosis factor antagonists
Required Medical Information	Documentation for evaluation of active or latent Tuberculosis (TB). For new starts only: at least 2 weeks passed since administration of Herpes Zoster vaccine prior to the start of therapy.
Age Restrictions	Deny if less than 18 years
Prescriber Restrictions	Deny if not prescribed by rheumatologist or dermatologist
Coverage Duration	Indefinite
Other Criteria	Documentation of the following: plaque psoriasis and inadequate response or inability to tolerate both adalimumab (Humira) AND etanercept (Enbrel) or documentation demonstrating that a trial may be inappropriate

TAVALISSE

Products Affected

- TAVALISSE

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	Documentation of baseline platelet count less than 30,000/mcL
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	Prescribed by or in consultation with hematologist/oncologist
Coverage Duration	Initial and Continuation criteria is 12 months
Other Criteria	Approved when there is documentation of an inadequate response or inability to tolerate ONE of the following: 1) Corticosteroids, 2) Immunoglobulins, 3) Splenectomy, 4) Thrombopoietin receptor agonists (e.g., Nplate, Promacta), or 5) rituximab (Rituxan). Continuation criteria: Fostamatinib (Tavalisse™) is re-approved when there is documentation of a positive clinical response to Tavalisse™ therapy as evidenced by an increase in platelet count to a level sufficient to avoid clinically important bleeding.

TESTOSTERONE PRODUCTS

Products Affected

- *testosterone transdermal gel 10 mg/act (2%), 12.5 mg/act (1%), 25 mg/2.5gm (1%), 50 mg/5gm (1%)*
- *testosterone transdermal solution*

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	Normal prolactin level, low (morning) testosterone level [For new starts only]
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Remainder of contract year
Other Criteria	Documentation of ONE of the following (1) negative history of prostate and breast cancer OR (2) history of prostate cancer staus post prostatectomy and documentation that the risk versus benefit has been assessed

TOPICAL RETINOID PRODUCTS

Products Affected

- *adapalene external cream*
- *adapalene external gel*
- *adapalene-benzoyl peroxide*
- ATRALIN
- AVITA
- *clindamycin-tretinoin*
- DIFFERIN
- EPIDUO
- EPIDUO FORTE
- RETIN-A
- RETIN-A MICRO
- RETIN-A MICRO PUMP EXTERNAL GEL 0.06 %, 0.08 %
- *tretinoin external*
- *tretinoin microsphere*
- ZIANA

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	Cosmetic use
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Remainder of contract year
Other Criteria	

TREMFYA

Products Affected

- TREMFYA

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	Concurrent therapy with biological DMARDs or other tumor necrosis factor antagonists
Required Medical Information	Documentation for evaluation of active or latent Tuberculosis (TB). For new starts only: at least 2 weeks passed since administration of live vaccines prior to the start of therapy.
Age Restrictions	Deny if less than 18 years
Prescriber Restrictions	Deny if not prescribed by a dermatologist
Coverage Duration	Indefinite
Other Criteria	Documentation of the following: plaque psoriasis and inadequate response or inability to tolerate both adalimumab (Humira) AND etanercept (Enbrel) or documentation demonstrating that a trial may be inappropriate

TYSABRI

Products Affected

- TYSABRI

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	Concurrent use of immunosuppressants or TNF inhibitors
Required Medical Information	
Age Restrictions	Deny if less than 18 years
Prescriber Restrictions	Deny if not prescribed by neurologist or gastroenterologist
Coverage Duration	End of contract year
Other Criteria	Subject to Part B vs Part D review and if part D is medically necessary when there is documentation of ONE of the following: (1) diagnosis of Crohn's disease with an inadequate response or inability to tolerate BOTH of the following: (a) ONE of the following: Corticosteroids, Aminosalicylates, Immunomodulators (ex. Azathioprine, 6-mercaptopurine), AND (b) ONE tumor necrosis factor-alpha (TNF-alpha) OR (2) diagnosis of Multiple sclerosis and inadequate response or inability to tolerate ONE alternative MS therapy (ie Avonex, Betaseron, Copaxone, Tecfidera, etc)

UPTRAVI

Products Affected

- UPTRAVI

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	Not taken in combination with a prostanoid/prostacyclin analogue (e.g. epoprostenol, iloprost, treprostinil)
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Deny if not prescribed by Cardiologist or Pulmonologist
Coverage Duration	6 month for initial authorization and 12 months for re-authorizations
Other Criteria	Approved when ALL of the following inclusion criteria are met: (1) Diagnosis of pulmonary arterial hypertension (PAH) WHO Group I with New York Heart Association (NYHA) Functional Class II to IV AND (2) Diagnosis confirmed by catheterization (right-heart or Swan-Ganz) or echocardiography AND (3) Documentation of mean pulmonary artery pressure greater than or equal to 25 mm Hg at rest or greater than 30 mm Hg with exertion AND (4) inadequate response or inability to tolerate TWO of the following (a) an endothelin receptor antagonist (Tracleer if naive to the class) (b) a phosphodiesterase inhibitor (sildenafil if naive to the class) (c) riocuguat (Adempas). RE-AUTHORIZATION CRITERIA: Documentation of stabilization or improvement as evaluated by a cardiologist or pulmonologist.

VALCHLOR

Products Affected

- VALCHLOR

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	Documentation of a diagnosis of Stage 1A and 1B mycosis fungoides-type cutaneous T-cell lymphoma in patients who have received prior skin-directed therapy

VECAMYL

Products Affected

- VECAMYL

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	Uremia, glaucoma, organic pyloric stenosis, coronary insufficiency, recent myocardial infarction
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Indefinite
Other Criteria	Documentation of BOTH of the following: (1) diagnosis of moderately severe to severe essential hypertension or malignant hypertension AND (2) an inadequate response or inability to tolerate at least two antihypertensive medications in different classes

VYVANSE

Products Affected

- VYVANSE

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	Deny if less than 6 years
Prescriber Restrictions	
Coverage Duration	Indefinite
Other Criteria	Documentation of ONE of the following: (1) Diagnosis of ADHD and inadequate response or inability to tolerate one of the following: immediate release formulations of amphetamine, dextroamphetamine, or methylphenidate, OR (2) diagnosis of binge eating disorder

XELJANZ

Products Affected

- XELJANZ
- XELJANZ XR

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	Concurrent therapy with any other biologic disease modifying anti-rheumatic drug (DMARD), e.g. tumor necrosis factor antagonists or potent immunosuppressants such as azathioprine or cyclosporine
Required Medical Information	Documentation for evaluation of active or latent Tuberculosis (TB)
Age Restrictions	Deny if less than 18 years
Prescriber Restrictions	Recommended by a Gastroenterologist or Rheumatologist
Coverage Duration	Indefinite
Other Criteria	Inadequate response or inability to tolerate methotrexate AND ONE of the following: (1) inadequate response or inability to tolerate adalimumab (Humira) AND etanercept (Enbrel) or (2) documentation demonstrating that a trial may be inappropriate

XENAZINE/AUSTEDO

Products Affected

- AUSTEDO
- *tetrabenazine*
- XENAZINE

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Prescribed by or in consultation with a neurologist
Coverage Duration	Indefinite
Other Criteria	Tetrabenazine (Xenazine) or Deutetrabenazine (Austedo) is approved when BOTH of the following are met: 1. Used for the treatment of chorea associated with Huntington's disease, and 2. Prescribed by or in consultation with a neurologist

XEOMIN

Products Affected

- XEOMIN INTRAMUSCULAR SOLUTION RECONSTITUTED 50 UNIT

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	Deny if less than 18 years
Prescriber Restrictions	
Coverage Duration	Indefinite
Other Criteria	Subject to Part B vs Part D review and if part D is medically necessary when ONE of the following is met: (1) blepharospasm in adults previously treated with Onabotulinumtoxin A (Botox) or (2) cervical dystonia (spasmodic torticollis), (3) or upper limb spasticity

XERMELO

Products Affected

- XERMELO

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	Deny if less than 18 years
Prescriber Restrictions	Prescribed by or in consultation with one of the following: a. Oncologist, b. Endocrinologist, c. Gastroenterologist
Coverage Duration	12 months for Initial, Indefinite for Reauthorization
Other Criteria	Telotristat (Xermelo) is approved when ALL of the following are met: 1. Diagnosis of carcinoid syndrome diarrhea, and 2. Diarrhea is inadequately controlled by a stable dose of somatostatin analog (SSA) therapy (e.g., octreotide [Sandostatin, Sandostatin LAR], lanreotide [Somatuline Depot]) for at least 3 months, and 3. Used in combination with SSA therapy REAUTHORIZATION CRITERIA Telotristat (Xermelo) is reapproved when BOTH of the following are met: 1. Documentation of positive clinical response to Xermelo therapy, and 2. Xermelo will continue to be used in combination with SSA therapy

XGEVA

Products Affected

- XGEVA

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	Prevention of skeletal-related events in patients with multiple myeloma
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Indefinite
Other Criteria	Subject to Part B vs Part D review and if part D is medically necessary necessary when there is documentation of ONE of the following diagnoses: (1) Bone metastases from solid tumors OR (2) Giant cell tumor of the bone (in adults and skeletally mature adolescents) that is unresectable or where surgical resection is likely to result in severe morbidity OR (3) hypercalcemia of malignancy refractory to bisphosphonates

XOLAIR

Products Affected

- XOLAIR

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	Deny if patient is less than 6 years
Prescriber Restrictions	Prescribed by Allergist, Dermatologist, Immunologist, or Pulmonologist
Coverage Duration	Indefinite
Other Criteria	Subject to Part B vs Part D review and if part D is medically necessary FOR DIAGNOSIS OF MODERATE TO SEVERE PERSISTENT ASTHMA: Documentation of ALL of the following: (1) The individual has a positive skin test or in vitro reactivity to a perennial aeroallergen, (2) The individual has a baseline serum IgE level of between 30 IU/mL and 700 IU/mL AND (3) Inadequate response or inability to tolerate a combination of high-dose inhaled corticosteroids (ICS) with a long-acting beta-agonist (LABA). FOR DIAGNOSIS OF CHRONIC URTICARIA: Documentation of an inadequate response or inability to tolerate ONE second-generation antihistamine at the maximum recommended doses in addition to ANY of the following: (a) leukotriene receptor antagonist (e.g.. montelukast) (b) histamine H2-receptor antagonist (e.g. ranitidine, cimetidine, famotidine), (c) substituting to a different second-generation antihistamine, (d) systemic glucocorticosteroids or (e) cyclosporine

XYREM

Products Affected

- XYREM

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	recommended by a neurologist or sleep specialist
Coverage Duration	3 months (initial and reauthorization)
Other Criteria	Documentation of 1) cataplexy in narcolepsy OR 2) excessive daytime sleepiness in narcolepsy with inadequate response or inability to modafanil. REAUTHORIZATION CRITERIA: Documentation to support the efficacy associated with the current regimen (including but not limited to reduction in the frequency of cataplexy attacks or an improvement in the Epworth sleepiness scale) AND re-evaluated every 3 months

ZAVESCA

Products Affected

- *miglustat*
- ZAVESCA

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	Deny if less than 18 years
Prescriber Restrictions	
Coverage Duration	Remainder of contract year
Other Criteria	Documentation of mild to moderate type 1 Gaucher disease AND enzyme replacement therapy is not a therapeutic option (e.g. because of allergy, hypersensitivity, or poor venous access).

ZINPLAVA

Products Affected

- ZINPLAVA

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	Deny if less than 18 years old
Prescriber Restrictions	Infectious disease specialist or gastroenterologist
Coverage Duration	one month
Other Criteria	Subject to Part B vs Part D review and if part D is medically necessary when there is documentation of ALL of the following: (1) confirmed diagnosis of C. difficile infection (2) Patient is at high risk for recurrence of C. difficile infection as documented by any of the following: (a) age ? 65 years, (b) use of systemic non-C. difficile antibiotics, (c) use of proton pump inhibitors, (d) underlying comorbidities that will predispose member to recurrence of C. difficile infection (eg immunocompromised, prior episode of C. difficile infection, etc), (e) recent hospitalization (3) bezlotoxumab will be administered in combination with standard antibiotics to reduce recurrent CDI (ie metronidazole, vancomycin administered enterally, fidaxomycin).

ZORBTIVE

Products Affected

- ZORBTIVE

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 weeks
Other Criteria	Used in conjuction with optimal management for short bowel syndrome, including specialized nutrition support

ZURAMPIC

Products Affected

- ZURAMPIC

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Indefinite
Other Criteria	Documentation of concurrent use of a xanthine oxidase inhibitor

Index

ABRAXANE 106
ABSTRAL 21
ACTEMRA 4, 5
ACTIQ 21
ACTIVELLA 71
adapalene external cream 163
adapalene external gel 163
adapalene-benzoyl peroxide 163
ADCIRCA 128
ADEMPAS 9
ADRIAMYCIN INTRAVENOUS SOLUTION 106
ADRUCIL INTRAVENOUS SOLUTION 500 MG/10ML 106
AFINITOR 118
AFINITOR DISPERZ 118
AFREZZA INHALATION POWDER 12 UNIT, 4 & 8 & 12 UNIT, 4 (90) & 8 (90) UNIT, 4 UNIT, 8 UNIT 10
AIMOVIG 140 DOSE 26
ALDURAZYME 11
ALECENSA 118
ALIMTA 106
ALIQOPA 106
ALKERAN INTRAVENOUS 106
ALLZITAL 69
ALORA 71
ALUNBRIG 118
AMABELZ 71
AMBIEN 74
AMBIEN CR 74
amitriptyline hcl oral 76
AMPYRA 13
AMRIX 75
ANADROL-50 14
ANAFRANIL 76
ANDRODERM TRANSDERMAL PATCH 24 HOUR 16
ANDROGEL 15
ANDROGEL PUMP TRANSDERMAL GEL 20.25 MG/ACT (1.62%) 15
ANGELIQ 71
ARALAST NP INTRAVENOUS SOLUTION RECONSTITUTED 1000 MG 140
armodafinil 133
ARRANON 106
ASCOMP-CODEINE 69
ATRALIN 163
AUBAGIO 101
AURYXIA 127
AUSTEDO 171
AVASTIN 106
AVITA 163
AVYCAZ 105
azacitidine 106
BAVENCIO 106
BELBUCA BUCCAL FILM 300 MCG, 450 MCG, 600 MCG, 750 MCG, 900 MCG 65
BELEODAQ 106
BELSOMRA 17
BENLYSTA 18
BENTYL INTRAMUSCULAR 69
benztropine mesylate injection 69
benztropine mesylate oral 69
BERINERT 8
bexarotene 118
BICNU 106
BIVIGAM INTRAVENOUS SOLUTION 10 GM/100ML 86
bleomycin sulfate injection solution reconstituted 30 unit 106
bortezomib 106
BOSULIF 118
BOTOX 19
BUPAP ORAL TABLET 50-300 MG 69
busulfan 106
BUSULFEX 106
butalbital-acetaminophen oral tablet 69
butalbital-apap-caff-cod 69
butalbital-apap-caffeine oral capsule 69
butalbital-apap-caffeine oral tablet 50-325-40 mg 69
butalbital-asa-caff-codeine 69
butalbital-aspirin-caffeine oral capsule 69
CABOMETYX 118
CALQUENCE 118
CAMPTOSAR INTRAVENOUS SOLUTION 100 MG/5ML 106
CAPRELSA 118
CARBAGLU 22
carbinoxamine maleate oral solution 69
carbinoxamine maleate oral tablet 4 mg 69
carboplatin intravenous solution 150 mg/15ml 106
CARIMUNE NF INTRAVENOUS SOLUTION RECONSTITUTED 6 GM 86

carisoprodol oral 75
carisoprodol-aspirin 75
carisoprodol-aspirin-codeine 75
CAYSTON 23
CERDELGA 24
CEREZYME INTRAVENOUS SOLUTION RECONSTITUTED 400 UNIT 57
CESAMET 25
chlordiazepoxide hcl 69
chlordiazepoxide-amitriptyline 76
chlorpropamide 73
chlorzoxazone oral tablet 500 mg 69
CHOLBAM 27
CIALIS ORAL TABLET 2.5 MG, 5 MG 28
CIMZIA PREFILLED 29
CIMZIA SUBCUTANEOUS KIT 2 X 200 MG 29
CINRYZE 30
cisplatin intravenous solution 50 mg/50ml 106
cladribine intravenous solution 10 mg/10ml 106
clemastine fumarate oral tablet 2.68 mg 69
CLIMARA 71
CLIMARA PRO 71
clindamycin-tretinoin 163
clofarabine 106
CLOLAR 106
clomipramine hcl oral 76
COGENTIN 69
COMBIPATCH 71
COMETRIQ (100 MG DAILY DOSE) 118
COMETRIQ (140 MG DAILY DOSE) 118
COMETRIQ (60 MG DAILY DOSE) 118
CORLANOR 31
COSENTYX 300 DOSE 32
COSENTYX SENSOREADY 300 DOSE 32
COSMEGEN 106
COTELLIC 118
CRESEMBA ORAL 33
CUBICIN 105
cyclobenzaprine hcl oral 75
CYRAMZA 106
CYSTARAN 34
cytarabine (pf) injection solution 100 mg/ml 106
cytarabine injection solution 106
dacarbazine intravenous solution reconstituted 200 mg 106
DACOGEN 106
dactinomycin 106
DAKLINZA 63
DALVANCE 105
daptomycin intravenous solution reconstituted 500 mg 105
DARZALEX INTRAVENOUS SOLUTION 100 MG/5ML 106
decitabine 106
DEMEROL INJECTION SOLUTION 25 MG/ML, 50 MG/ML 69
dexrazoxane intravenous solution reconstituted 250 mg 106
diclofenac sodium transdermal gel 3 % 36
dicyclomine hcl intramuscular 69
dicyclomine hcl oral 69
DIFFERIN 163
DIFICID 37
DIGITEK ORAL TABLET 250 MCG 69
DIGOX ORAL TABLET 250 MCG 69
digoxin injection 69
digoxin oral tablet 250 mcg 69
DILAUDID ORAL TABLET 4 MG, 8 MG 65
dipyridamole oral 69
DIVIGEL TRANSDERMAL GEL 1 MG/GM 71
docetaxel intravenous concentrate 80 mg/4ml 106
docetaxel intravenous solution 160 mg/16ml 106
DOLOPHINE 65
DOPTELET ORAL TABLET 20 MG 38
doxepin hcl oral 76
DOXIL 106
doxorubicin hcl intravenous solution 106
doxorubicin hcl liposomal 106
DUPIXENT 39
DURAGESIC-100 65
DURAGESIC-25 65
DURAGESIC-50 65
DURAGESIC-75 65
DYSPORT 40
EDLUAR 74
EGRIFTA SUBCUTANEOUS SOLUTION RECONSTITUTED 1 MG 41
ELAPRASE 42
ELELYSO 57
ELESTRIN 71
ELLENCE INTRAVENOUS SOLUTION 200 MG/100ML 106
EMBEDA 3, 65

EMFLAZA 43
EMPLICITI 106
EMSAM 44
ENBREL SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 45
ENBREL SUBCUTANEOUS SOLUTION RECONSTITUTED 45
ENBREL SURECLICK SUBCUTANEOUS SOLUTION AUTO-INJECTOR 45
ENDARI 46
EPCLUSA 47
EPIDUO 163
EPIDUO FORTE 163
epirubicin hcl intravenous solution 200 mg/100ml 106
ERBITUX INTRAVENOUS SOLUTION 100 MG/50ML 106
ergoloid mesylates oral 69
ERIVEDGE 118
ERLEADA 118
ERWINAZE INJECTION 106
ESBRIET 134
ESGIC ORAL TABLET 69
ESTRACE ORAL 71
estradiol oral 71
estradiol transdermal 71
estradiol-norethindrone acet 71
eszopiclone 74
ETOPOPHOS 106
etoposide intravenous solution 100 mg/5ml 106
EUCRISA 48
EVAMIST 71
EXALGO ORAL TABLET ER 24 HOUR ABUSE-DETERRENT 65
EXJADE 35
EXONDYS 51 49
FABRAZYME 50
FARYDAK 118
FEMHRT LOW DOSE 71
fentanyl citrate buccal 51
fentanyl transdermal patch 72 hour 100 mcg/hr, 25 mcg/hr, 37.5 mcg/hr, 50 mcg/hr, 62.5 mcg/hr, 75 mcg/hr, 87.5 mcg/hr 65
FENTORA BUCCAL TABLET 100 MCG, 200 MCG, 400 MCG, 600 MCG, 800 MCG . 21
FERRIPROX 52
FEXMID 75
FIORICET ORAL CAPSULE 69
FIORICET/CODEINE ORAL CAPSULE 50-300-40-30 MG 69
FIORINAL 69
FIORINAL/CODEINE #3 69
FIRAZYR 8
FLEBOGAMMA DIF INTRAVENOUS SOLUTION 5 GM/50ML 86
FLECTOR 53
fludarabine phosphate intravenous solution reconstituted 106
fluorouracil intravenous solution 5 gm/100ml 106
flurazepam hcl 69
FOLOTYN INTRAVENOUS SOLUTION 40 MG/2ML 106
FORTEO SUBCUTANEOUS SOLUTION 600 MCG/2.4ML 54
FORTESTA 16
FYAVOLV 71
GAMMAGARD INJECTION SOLUTION 2.5 GM/25ML 86
GAMMAGARD S/D LESS IGA 86
GAMMAKED INJECTION SOLUTION 1 GM/10ML 86
GAMMAPLEX INTRAVENOUS SOLUTION 10 GM/100ML, 10 GM/200ML, 20 GM/200ML, 5 GM/50ML 86
GAMUNEX-C INJECTION SOLUTION 1 GM/10ML 86
GATTEX 56
gemcitabine hcl intravenous solution reconstituted 1 gm 106
GEMZAR INTRAVENOUS SOLUTION RECONSTITUTED 1 GM 106
GENOTROPIN 60
GENOTROPIN MINIQUICK 60
GILENYA ORAL CAPSULE 0.5 MG 101
GILOTRIF 118
GLASSIA 140
GLEEVEC 118
GLEOSTINE ORAL CAPSULE 10 MG, 100 MG, 40 MG 118
glyburide micronized 73
glyburide oral 73
glyburide-metformin 73
GLYNASE 73
GOCOVRI 58
GRALISE 59

GRALISE STARTER 59
HAEGARDA 30
HALAVEN 106
HARVONI 62
HERCEPTIN 106
HETLIOZ 64
HORIZANT ORAL TABLET EXTENDED RELEASE 68
HP ACTHAR 6
HUMATROPE 60
HUMIRA PEDIATRIC CROHNS START SUBCUTANEOUS PREFILLED SYRINGE KIT 40 MG/0.8ML, 80 MG/0.8ML, 80 MG/0.8ML & 40MG/0.4ML 77
HUMIRA PEN SUBCUTANEOUS PEN-INJECTOR KIT 77
HUMIRA PEN-CD/UC/HS STARTER 77
HUMIRA PEN-PS/UV STARTER 77
HUMIRA SUBCUTANEOUS PREFILLED SYRINGE KIT 77
HUMULIN R U-500 (CONCENTRATED) 78
HUMULIN R U-500 KWIKPEN SUBCUTANEOUS SOLUTION PEN-INJECTOR 78
HYCAMTIN INTRAVENOUS 106
hydromorphone hcl er 65
hydromorphone hcl oral tablet 4 mg, 8 mg 65
hydroxyzine hcl intramuscular 69
hydroxyzine hcl oral syrup 69
hydroxyzine hcl oral tablet 69
hydroxyzine pamoate oral 69
HYSINGLA ER 3, 65
IBRANCE 118
ICLUSIG 118
IDAMYCIN PFS INTRAVENOUS SOLUTION 20 MG/20ML 106
idarubicin hcl intravenous solution 10 mg/10ml 106
IDHIFA 118
IFEX INTRAVENOUS SOLUTION RECONSTITUTED 1 GM 106
ifosfamide intravenous solution reconstituted 1 gm 106
ILARIS SUBCUTANEOUS SOLUTION 79
imatinib mesylate 118
IMBRUVICA 118
IMFINZI 106
imipramine hcl oral 76
imipramine pamoate 76
IMVEXXY MAINTENANCE PACK VAGINAL INSERT 10 MCG 127
INCRELEX 80
INDOCIN ORAL 69
indomethacin er 69
indomethacin oral 69
INFLECTRA 81
INGREZZA 83
INLYTA 118
INTERMEZZO 74
INTRAROSA 127
IRESSA 118
irinotecan hcl intravenous solution 100 mg/5ml 106
ISTODAX (OVERFILL) 106
JADENU 35
JADENU SPRINKLE 35
JAKAFI 118
JEVTANA 106
JINTELI 71
JUXTAPID 67
JYNARQUE 88
KADCYLA 106
KADIAN ORAL CAPSULE EXTENDED RELEASE 24 HOUR 100 MG, 200 MG, 80 MG 65
KALYDECO 89
KANUMA 90
KARBINAL ER ORAL SUSPENSION EXTENDED RELEASE 69
ketorolac tromethamine injection solution 15 mg/ml, 30 mg/ml 72
ketorolac tromethamine intramuscular solution 60 mg/2ml 72
ketorolac tromethamine oral 72
KEVEYIS 91
KEVZARA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 92
KEYTRUDA INTRAVENOUS SOLUTION 106
KINERET SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 93
KISQALI 200 DOSE 118
KISQALI 400 DOSE 118
KISQALI 600 DOSE 118
KISQALI FEMARA 200 DOSE 118
KISQALI FEMARA 400 DOSE 118
KISQALI FEMARA 600 DOSE 118
KORLYM 94

KYNAMRO SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 67
KYPROLIS INTRAVENOUS SOLUTION RECONSTITUTED 30 MG, 60 MG 106
LANOXIN INJECTION SOLUTION 0.25 MG/ML 69
LANOXIN ORAL TABLET 250 MCG 69
LARTRUVO 106
LAZANDA 21
LENVIMA 10 MG DAILY DOSE 118
LENVIMA 14 MG DAILY DOSE 118
LENVIMA 18 MG DAILY DOSE 118
LENVIMA 20 MG DAILY DOSE 118
LENVIMA 24 MG DAILY DOSE 118
LENVIMA 8 MG DAILY DOSE 118
LETAIRIS 120
lidocaine external patch 5 % 95
LIDODERM 95
linezolid intravenous solution 600 mg/300ml 105
linezolid oral 117
LONSURF 118
LORZONE 69
LUMIZYME 12
LUNESTA 74
LYNPARZA 118
LYRICA 96
LYRICA CR 96
MAKENA 97
MAVYRET 98
MEKINIST 118
melphalan hcl 106
MENOSTAR 71
meperidine hcl injection solution 100 mg/ml, 25 mg/ml, 50 mg/ml 69
meperidine hcl oral 69
meprobamate 69
METAXALL 69
metaxalone 69
methadone hcl oral solution 65
methadone hcl oral tablet 65
methocarbamol injection solution 1000 mg/10ml 69
methocarbamol oral 69
miglustat 177
MIMVEY 71
MIMVEY LO 71
MINIVELLE 71
mitomycin intravenous 106
mitoxantrone hcl intravenous concentrate 25 mg/12.5ml 106
modafinil 99
morphine sulfate er beads oral capsule extended release 24 hour 120 mg 65
morphine sulfate er oral capsule extended release 24 hour 100 mg, 60 mg, 80 mg 65
morphine sulfate er oral tablet extended release 100 mg, 200 mg, 60 mg 65
MOZOBIL 100
MS CONTIN ORAL TABLET EXTENDED RELEASE 100 MG, 200 MG, 60 MG 65
MUSTARGEN 106
MYALEPT 102
MYLOTARG INTRAVENOUS SOLUTION RECONSTITUTED 4.5 MG 106
MYTESI 55
NATPARA 103
NERLYNX 118
NEXAVAR 118
NINLARO 118
NIPENT 106
NORDITROPIN FLEXPRO 60
norethindrone-eth estradiol 71
nortriptyline hcl oral 76
NOXAFIL ORAL 109
NUCALA 110
NUCYNTA ER 3, 65
NUCYNTA ORAL TABLET 100 MG, 75 MG 65
NUEDEXTA 111
NULOJIX 112
NUPLAZID ORAL TABLET 17 MG 113
NUTROPIN AQ NUSPIN 10 60
NUTROPIN AQ NUSPIN 20 60
NUTROPIN AQ NUSPIN 5 60
NUVIGIL 133
OCALIVA 114
OCTAGAM INTRAVENOUS SOLUTION 1 GM/20ML, 2 GM/20ML 86
ODOMZO 118
OFEV 134
OLUMIANT 115
OMNITROPE 60
OPANA ORAL TABLET 10 MG 65
OPDIVO INTRAVENOUS SOLUTION 100 MG/10ML, 40 MG/4ML 106
OPSUMIT 120
ORACEA 116

ORALAIR 121
ORBACTIV 105
ORENCIA CLICKJECT 123
ORENCIA INTRAVENOUS 122
ORENCIA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 123
ORENITRAM 120
ORKAMBI ORAL TABLET 124
orphenadrine citrate er 69
orphenadrine citrate injection 69
OSPHENA 127
OTEZLA ORAL TABLET 125
OTEZLA ORAL TABLET THERAPY PACK 125
OTREXUP SUBCUTANEOUS SOLUTION AUTO-INJECTOR 10 MG/0.4ML, 12.5 MG/0.4ML, 15 MG/0.4ML, 17.5 MG/0.4ML, 20 MG/0.4ML, 22.5 MG/0.4ML, 25 MG/0.4ML 85
oxaliplatin intravenous solution 100 mg/20ml 106
oxaliplatin intravenous solution reconstituted 100 mg 106
oxycodone hcl er oral tablet er 12 hour abuse-deterrent 30 mg, 40 mg, 60 mg, 80 mg 65
oxycodone hcl oral tablet 30 mg 65
OXYCONTIN ORAL TABLET ER 12 HOUR ABUSE-DETERRENT 10 MG, 20 MG 3
OXYCONTIN ORAL TABLET ER 12 HOUR ABUSE-DETERRENT 30 MG, 40 MG, 60 MG, 80 MG 65
oxymorphone hcl er oral tablet extended release 12 hour 20 mg, 30 mg, 40 mg 65
oxymorphone hcl oral tablet 10 mg 65
paclitaxel intravenous concentrate 100 mg/16.7ml 106
PALYNZIQ 126
PAMELOR ORAL CAPSULE 76
pentazocine-naloxone hcl 69
PERJETA 106
perphenazine-amitriptyline 76
PHENADOZ RECTAL SUPPOSITORY 12.5 MG 69
PHENERGAN INJECTION 69
PHRENILIN FORTE ORAL CAPSULE 50-300-40 MG 69
PICATO 129
POMALYST 118
PRALUENT SUBCUTANEOUS SOLUTION PEN-INJECTOR 130
PREFEST 71
PREMARIN INJECTION 71
PREMARIN ORAL 71
PRIVIGEN INTRAVENOUS SOLUTION 20 GM/200ML 86
PROCYSBI 131
PROLASTIN-C INTRAVENOUS SOLUTION RECONSTITUTED 1000 MG 140
PROLIA 132
promethazine hcl injection 69
promethazine hcl oral syrup 69
promethazine hcl oral tablet 69
promethazine hcl rectal 69
promethazine vc plain oral solution 69
PROMETHEGAN RECTAL SUPPOSITORY 25 MG, 50 MG 69
PROVIGIL 133
QUALAQUIN 135
quinine sulfate oral 135
RADICAVA 136
RASUVO SUBCUTANEOUS SOLUTION AUTO-INJECTOR 10 MG/0.2ML, 12.5 MG/0.25ML, 15 MG/0.3ML, 17.5 MG/0.35ML, 20 MG/0.4ML, 22.5 MG/0.45ML, 25 MG/0.5ML, 30 MG/0.6ML, 7.5 MG/0.15ML 85
RAVICTI 137
REMICADE 81
REMODULIN 138
RENFLEXIS 81
REPATHA 139
REPATHA PUSHTRONEX SYSTEM 139
REPATHA SURECLICK 139
RETIN-A 163
RETIN-A MICRO 163
RETIN-A MICRO PUMP EXTERNAL GEL 0.06 %, 0.08 % 163
REVATIO 128
REVLIMID 118
RITUXAN INTRAVENOUS SOLUTION 106
ROBAXIN INJECTION SOLUTION 1000 MG/10ML 69
ROXICODONE ORAL TABLET 30 MG 65
RUBRACA 118
RUCONEST 8
RYDAPT 118

RYVENT 69
SAIZEN 60
SAIZENPREP 60
SAMSCA 141
SANCUSO 25
SAVELLA 142
SAVELLA TITRATION PACK 142
SEROSTIM SUBCUTANEOUS SOLUTION RECONSTITUTED 4 MG, 5 MG, 6 MG 143
SIGNIFOR 144
SIGNIFOR LAR INTRAMUSCULAR SUSPENSION RECONSTITUTED ER 20 MG, 40 MG, 60 MG 145
sildenafil citrate intravenous 146
sildenafil citrate oral tablet 20 mg 146
SILENOR 147
SILIQ 148
SIMPONI ARIA 150
SIMPONI SUBCUTANEOUS SOLUTION AUTO-INJECTOR 149
SIMPONI SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 149
SIRTURO 151
SIVEXTRO 105, 117
SKELAXIN 69
SOMA 75
SONATA 74
SOVALDI 63
SPRYCEL 118
STELARA INTRAVENOUS 152
STELARA SUBCUTANEOUS SOLUTION 45 MG/0.5ML 152
STELARA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 152
STIVARGA 118
STRENSIQ SUBCUTANEOUS SOLUTION 40 MG/ML, 80 MG/0.8ML 153
STRIANT 16
SUBSYS SUBLINGUAL LIQUID 100 MCG, 200 MCG, 400 MCG, 600 MCG, 800 MCG 21
SURMONTIL 76
SUTENT 118
SYLATRON SUBCUTANEOUS KIT 200 MCG, 300 MCG, 600 MCG 154
SYLVANT 155
SYMDEKO 156
SYMLINPEN 120 SUBCUTANEOUS SOLUTION PEN-INJECTOR 157
SYMLINPEN 60 SUBCUTANEOUS SOLUTION PEN-INJECTOR 157
SYNAGIS 158
SYNERCID 105
SYNRIBO 106
TAFINLAR 118
TAGRISSO 118
TALTZ 160
TARCEVA 118
TARGRETIN ORAL 118
TASIGNA 118
TAVALISSE 161
TAXOTERE INTRAVENOUS CONCENTRATE 80 MG/4ML 106
TECENTRIQ 106
TECHNIVIE 63
TEFLARO 105
TENCON ORAL TABLET 50-325 MG 69
TESTIM 16
testosterone transdermal gel 10 mg/act (2%), 12.5 mg/act (1%), 25 mg/2.5gm (1%), 50 mg/5gm (1%) 162
testosterone transdermal solution 162
tetrabenazine 171
THALOMID 118
thiotepa injection 106
TIVORBEX 69
TOBI PODHALER 84
TOPOSAR INTRAVENOUS SOLUTION 1 GM/50ML 106
topotecan hcl intravenous solution reconstituted 106
TORISEL 106
TRACLEER 120
TREANDA INTRAVENOUS SOLUTION RECONSTITUTED 106
TREMFYA 164
tretinoin external 163
tretinoin microsphere 163
trihexyphenidyl hcl 69
trimipramine maleate oral 76
TRISENOX INTRAVENOUS SOLUTION 12 MG/6ML 106
TYKERB 118
TYMLOS 54
TYSABRI 165
UPTRAVI 166

VABOMERE 105
VALCHLOR 167
VANATOL LQ 69
VECAMYL 168
VECTIBIX INTRAVENOUS SOLUTION 100 MG/5ML 106
VELCADE INJECTION 106
VENCLEXTA 118
VENCLEXTA STARTING PACK 118
VENTAVIS 104
VERZENIO 118
VIDAZA 106
VIEKIRA PAK 63
VIEKIRA XR 63
vinblastine sulfate intravenous solution 106
VINCASAR PFS 106
vincristine sulfate intravenous 106
vinorelbine tartrate intravenous solution 50 mg/5ml 106
VISTARIL 69
VIVELLE-DOT 71
VOGELXO PUMP 16
VOGELXO TRANSDERMAL GEL 50 MG/5GM (1%) 16
VOSEVI 63
VOTRIENT 118
VPRIV 57
VYVANSE 169
VYXEOS INTRAVENOUS SUSPENSION RECONSTITUTED 44-100 MG 106
XALKORI 118
XELJANZ 170
XELJANZ XR 170
XENAZINE 171
XEOMIN INTRAMUSCULAR SOLUTION RECONSTITUTED 50 UNIT 172
XERMELO 173
XGEVA 174
XOLAIR 175
XTAMPZA ER 3, 65
XTANDI 118
XYREM 176
YERVOY INTRAVENOUS SOLUTION 50 MG/10ML 106
YONDELIS 106
YONSA 118
zaleplon 74
ZALTRAP INTRAVENOUS SOLUTION 100 MG/4ML 106
ZANOSAR 106
ZAVESCA 177
ZEBUTAL ORAL CAPSULE 50-325-40 MG 69
ZEJULA 118
ZELBORAF 118
ZEMAIRA 140
ZEPATIER 63
ZERBAXA 105
ZIANA 163
ZINECARD INTRAVENOUS SOLUTION RECONSTITUTED 250 MG 106
ZINPLAVA 178
ZOHYDRO ER ORAL CAPSULE ER 12 HOUR ABUSE-DETERRENT 3
ZOLINZA 118
zolpidem tartrate 74
zolpidem tartrate er 74
ZOMACTON 60
ZORBTIVE 179
ZURAMPIC 180
ZYDELIG 118
ZYKADIA 118
ZYTIGA 118
ZYVOX INTRAVENOUS SOLUTION 600 MG/300ML 105
ZYVOX ORAL 117